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The mammary gland is a branched, secretory organ that that is composed of diverse 
cells types. The populations that comprise the mammary epithelium include mammary stem cells, 
lineage-restricted progenitors, and differentiated luminal and basal cells. Breast cancer develops 
when one or a subset of these epithelial cells undergoes transformation, resulting in disease that 
can vary broadly in pathology and prognosis. For example, gene expression analysis of a large 
cohort of breast cancers has classified tumors into distinct subtypes, including: HER2-positive, 
Basal-Like, Luminal A, and Luminal B. Furthermore, hormone receptor status is also used in the 
clinic to classify tumors and define the course of treatment. Factors that may contribute to this 
broad breast cancer diversity are still unclear; however, we hypothesize that breast cancer 
phenotype may be influenced by intrinsic properties of the originating cell.  
Therefore, to determine whether specific cells types influence breast cancer pathology, 
the goal of this dissertation has been to develop a series of mouse models of breast cancer that 
can be used to target oncogene expression to distinct mammary epithelial cell (MEC) lineages. 
One such model was generated by infecting mouse MECs with a lentivirus expressing the 
polyoma virus middle T antigen oncogene, then cells were enriched for specific cell lineages 
using fluorescence activated cell sorting, and were orthotopically transplanted to generate 
tumors. Resulting tumors were classified by histology, estrogen receptor status, molecular 
subtype, and metastatic propensity. Our results demonstrated that each MEC population we 
evaluated could give rise to diverse tumor types; however, we also determined that MEC 
populations exhibited differences in their propensity for tumor histology, molecular subtype, and 
metastatic potential. 
Furthermore, we developed an additional approach of targeting specific gene expression 
to distinct MEC populations. In this system, lentiviral constructs were designed to express a 
specific gene after Cre-mediated recombination. Then, MECs isolated from mice that express Cre 
 iv 
through cell lineage-restricted promoters were infected with the lentivirus and orthotopically 
transplanted or analyzed by three-dimensional culture. We validated this approach by targeting 
fluorescent Tomato reporter and polyoma virus middle T antigen oncogene expression to specific 
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Mammary Gland Development 
The mammary gland is a unique mammalian organ specialized for the nourishment of 
newborn animals. It consists of diverse cell populations, including a densely branched epithelium 
that performs most of the organ’s essential secretory functions, and a variety of supporting cells 
such as adipocytes, vascular endothelial cells, fibroblasts, and immune cells. Proper development 
and morphogenesis of the ductal network are critical for generating a large surface area to 
produce an adequate milk supply for offspring during lactation (1).  
Most of what is known about human breast development has been discovered in studies 
analyzing mouse mammary glands. The majority of development for building the densely 
branched mouse mammary gland epithelium take place during two key postembryonic stages: 
ductal morphogenesis during puberty; and alveolar differentiation during pregnancy and lactation 
(1). Figure 1.1 summarizes the key stages of postnatal mouse mammary gland development, 
which are discussed below (adapted from Macias and Hinck, 2012 (1)). 
The initial stages of mammary gland growth begin by the middle of mouse 
embryogenesis, when cells migrating from the ectoderm form mammary placodes along the 
ventrally located mammary lines. Mesoderm-derived fibroblast cells also form a layer around the 
epithelial cells (2,3). By embryonic day 14, the rudimentary mammary gland develops into a bud 
that connects to the epidermis and extends into the dermal mesenchyme (1). As the mammary 
epithelium continues to grow, it reaches a fat pad derived from subcutaneous mesenchymal cells 
and begins to branch, forming a rudimentary ductal network containing a lumen (4-6). After this 
formation, most of the remaining growth and development occurs at puberty (Figure 1.1). 
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At birth, the mammary gland continues to grow in proportion with the animal’s body size 
until puberty. Once the mouse reaches puberty at 4 weeks, growth hormone (GH) produced by 
the pituitary gland induces insulin-like growth factor 1 (IGF1) secretion from the liver and 
mammary gland stroma (7,8). Then, IGF1, along with estrogen secreted from the ovaries (9,10), 
promote mammary epithelial cell proliferation at the ductal terminal end buds (TEBs). As the 
extending TEBs invade and fill the fat pad, the primary ducts undergo branching morphogenesis 
by dividing at TEBs to form secondary lateral branches (11). 
After the mouse reaches adulthood at 12 weeks, it begins to go through cycles of estrus. 
At this time, cycling of the ovarian hormone progesterone stimulates tertiary branch growth to 
prepare the mammary epithelium for expansion during pregnancy (Figure 1.1). With pregnancy, 
progesterone and pituitary gland-secreted prolactin hormones stimulate further branching and 
proliferation of milk secreting alveolar cells. Then, alveolar cells fill up the entirety of the 
mammary fat pad for maximal milk production (12-16). 
Lactation completes after the pups stop suckling, or are weaned. Weaning causes 
mammary gland engorgement and initiation of the first stage of involution, which is reversible 
within 48 hours by suckling. During this stage, alveolar cells begin to die and are shed into the 
ductal lumens (17-19). The second stage of involution occurs when alveolar cells collapse, a 
week after weaning, and a massive wave of apoptosis leads to mammary gland tissue 
remodeling into a pre-pregnancy state (20-22). 
In sum, the major mammary developmental events take place during puberty and 
pregnancy. These processes are essential for the generation of a highly branched ductal network 
for subsequent nourishment of mammalian newborns. Furthermore, the cycles of substantial 
proliferation, apoptosis, and tissue remodeling during pregnancy and involution indicate that the 
mammary epithelium is highly proliferatory and regenerative. 
 
Mammary Epithelial Cell Hierarchy 
Much of what we know about the cellular architecture of the breast epithelium comes 
from analyzing mouse mammary glands. Both the human and mouse mammary epithelium 
consists of a branched network of bilayered ducts that are predominantly composed of luminal 
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and basal cells (Figure 1.2A). Luminal cells populate the inner layer of mammary ducts and 
border a central lumen, whereas the outer layer, adjacent to the basement membrane, is 
populated by basal cells. This basal layer also contains rare mammary epithelial stem cells (23). 
The specific functions and characteristics of individual mammary epithelial cell populations are 
described below. 
 
Mammary stem cells and progenitors 
The mouse mammary gland is a highly regenerative organ. This was highlighted by early 
transplantation experiments, which demonstrated that fragments of mammary ducts implanted 
into epithelium-free, or “cleared”, mammary fat pads could reproduce the ductal network. These 
studies provided evidence for the presence of a mammary stem cell population in adult mammary 
tissue, a population that was later shown to be distributed throughout the length of the ductal 
structure (24-26).   
A distinct population of mammary gland repopulating cells, or stem cells, was initially 
described to reside in terminal end buds of developing ducts during puberty (11). Later 
fluorescence activated cell sorting (FACS) experiments were able to enrich for subsets of highly 
regenerative basal cells from the adult mammary epithelium that expressed high levels of the cell 
surface markers CD49f, CD29, and low to moderate levels of CD24 (27-30). However, these 
studies only enriched for mammary stem cells that were intermixed with basal cells, and did not 
isolate a pure population of stem cells. Based on mammary transplantation and repopulating 
assays, Shackleton et al. estimated that one out of 18 of these enriched basal cells was actually a 
mammary stem cell (27).  
To further delineate mammary stem cells from more differentiated basal populations, 
transgenic mice driving reporter expression through established stem cell promoters were also 
used to identify mammary stem cells. For example, the Leucine-rich repeat-containing G-protein 
coupled receptor 5  (LGR5) promoter, a Wnt target gene, is active in stem cells of several adult 
tissues, including the intestinal epithelium, skin, and kidney (31). In the mammary gland, Plaks et 
al. also demonstrated that LGR5-positive cells have a high repopulating capacity (32). However, 
other studies report that both LGR5-positive and negative mammary epithelial cells have stem 
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cell activity, indicating that the mammary stem cell population is heterogeneous (33,34). 
Furthermore, stem cells isolated from fetal and adult mammary glands also have different 
properties. Unlike adult mammary stem cells, which express basal cell surface markers and 
cytokeratins, fetal mammary stem cells display both basal and luminal lineage properties, and 
have a higher regenerative capacity (35,36). 
To add to the complexity of the mammary progenitor compartment, recent lineage tracing 
experiments using inducible Cre reporter mice have presented conflicting results about which 
MEC populations drive the propagation and maintenance of the ductal network during postnatal 
development. Van Keymeulen et al. demonstrated that after birth, lineage committed basal and 
luminal cell progenitors promote mammary gland growth and maintenance during puberty and 
pregnancy (37). However, recent studies have also demonstrated that a bipotent basal progenitor 
may be responsible for the maintenance of the mammary epithelium during postnatal 
development (34). Further studies need to be conducted to definitively differentiate between adult 
mammary stem cells, bipotent and multipotent progenitors. Figure 1.2B (adapted from Visvader 
and Stingl, 2014) summarizes the current hypothesized mammary epithelial cell hierarchy (38). 
 
Basal cells 
Basal cells populate the peripheral layer of the mammary duct epithelium and interact 
with the basement membrane. This layer consists of basal progenitors and more differentiated 
myoepithelial cells. The role of the myoepithelial cell population is to utilize smooth muscle 
contractile fibers to propel milk through the ductal network during lactation. Furthermore, the 
basal/myoepithelial cell layer acts as a barrier between the stroma and the mammary epithelium, 
which may suppress tumor growth and invasion into the basement membrane during mammary 
gland pathogenesis (39,40). 
As described above, basal/myoepithelial cells represent the major component of the 
mammary epithelial cell population which expresses high levels of cell surface markers CD49f, 
CD29, and low to moderate levels of CD24. There are some differences in the mammary 
repopulating capacities of basal cells expressing variable levels of FACS-detectable cell surface 
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markers; otherwise, stem cells, basal progenitors, and differentiated myoepithelial cells are 
difficult to distinguish (27-30).  
Morphologically, basal cells differ based on their location in the ductal network. Along the 
length of the ducts, basal cells are shaped like spindles and form a single continuous layer 
adjacent to the luminal cell compartment. At ductal termini, basal cells adopt a stellate shape and 
form web-like nets surrounding the terminal luminal cells, and alveoli during lactation (39,41).  
Much of basal cell function and shape is coordinated by smooth muscle actin and myosin 
fibers. During lactation, basal cells undergo further morphological changes to completely 
surround milk-producing alveoli, and contraction of the myoepithelial smooth muscle fibers is 
essential for the facilitation of milk ejection (41-43). Despite resembling and acting like smooth 
muscle cells, the basal lineage is derived from the ectoderm and can be identified by its 
expression of epithelial cytokeratins 5, 14, and 17 (37,39,44). 
Interactions between basal cells and their extracellular environment also play a critical 
role in their function. Basal cells are directly adjacent to the basement membrane, which 
surrounds the mammary epithelium and is composed of collagens and laminins (45). For 
example, integrins expressed by basal cells interact with the basement membrane to coordinate 
ductal branching morphogenesis and alveolar growth (46). Furthermore, basal cell-specific 
desmosomal junctions play a role in organizing the basal and luminal cell layers(47). The 
maintenance of apicobasal polarity by basal cell tight junctions may help inhibit tumor invasion 
into the basement membrane during breast pathogenesis (40). 
 
Luminal cells 
 The luminal cell population makes up the inner layer of the mammary duct. One function 
of the luminal cell compartment is to maintain mammary duct structural integrity. In addition, 
subsets of luminal cells respond to external hormonal cues such as estrogen, progesterone, and 
prolactin that activate proliferation during postnatal developmental stages and promote 
differentiation into milk secreting alveolar cells during pregnancy (1,23,38).  
The luminal compartment is composed of diverse populations of cells (Figure 1.2B). 
FACS analyses have demonstrated that luminal progenitors, alveolar progenitors, and hormone 
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receptor positive and negative populations can be distinguished based on differential expression 
of cell surface markers (38). For example, a majority of luminal cells express an abundance of 
CD24 and low levels of CD49f (27-29); however, differential expression of CD133 can be used to 
separate luminal cells into progenitor (CD133-) and more mature estrogen receptor positive 
(ER+, CD133+) populations (48). The distinct luminal cell populations vary in their survival 
capacity in colony forming assays, but typically do not form substantial outgrowths upon 
transplantation into cleared mammary fat pads (37,38). 
 Cell lineage tracing studies using transgenic Cre reporter mice have also been used to 
identify subsets of luminal cells. The promoters for E74-like factor 5 (Elf5), a transcription factor 
functioning downstream of prolactin signaling (49), and keratin 8 are active in luminal progenitors; 
however, it is not clear whether both of these promoters are active in the same populations 
(34,37,50). The hormonally-regulated whey acidic protein (WAP) promoter is active in luminal 
populations that differentiate into milk producing alveolar cells during late stages of pregnancy. 
Lineage tracing experiments have demonstrated that cells which expressed WAP can survive 
involution, and serve as a pool of alveolar precursors for subsequent rounds of pregnancy. 
However, WAP-positive cells do not contribute the differentiation of all luminal cell types, 
including the ER+ luminal population (51,52). Another hormone responsive promoter, the mouse 
mammary tumor virus (MMTV) long terminal repeat is active in large proportions of luminal cells 
(53).  Also, the Notch3 promoter is active in transiently quiescent luminal progenitors that give 
rise to both ER+ and ER- ductal cells (54).  
 Overall, the luminal compartment is composed of heterogeneous populations of cells. 
These cells include luminal lineage-restricted progenitors, alveolar precursors, and mature 
hormone receptor positive and negative cells. Further lineage tracing studies need to be 
performed to clearly define the broad number of potential luminal progenitors and their 








Transcriptional regulators of mammary 
epithelial cell fate 
The proper balance of stem, progenitor, and differentiated mammary epithelial cell 
populations is regulated by multiple transcription factors. Stem cell maintenance relies heavily on 
p63, Slug, Sox9, and Twist activities (55-57). Loss of these transcription factors can promote a 
luminal cell fate, and their overexpression leads to an increase of cells with basal and stem cell 
properties (58,59). Multiple cellular signaling components can downregulate stem cell 
transcription factors to promote luminal cell lineage commitment. For example, the Notch pathway 
inhibits p63 expression (60,61). In addition, ELF5 directly blocks Slug transcription to enhance 
luminal and alveolar cell development in response to progesterone signaling (50,62-64). Other 
transcription factors involved in luminal and alveolar cell commitment include Stat5a and Gata3 
(65-68). Improper activities of these cell fate regulators can inhibit mammary gland development 
or induce pathogenesis (69). 
 
Breast Cancer Diversity 
 Breast cancer is a heterogeneous disease. This is evidenced by recent genetic profiling 
studies that have identified at least five distinct molecular subtypes of breast cancer (70,71). In 
the clinic, breast tumors are also classified by their histological grade, hormone receptor status, 
and growth factor receptor expression (72). Both molecular and histological characteristics of 
breast tumors help predict disease outcome and decide the course of treatment. The purpose of 
this section is to give an overview of the major breast cancer subtypes and highlight the broad 
heterogeneity that this disease presents. 
 Before the development of molecular classification techniques, tumor histology has been 
the gold standard for describing breast cancer subtype, and is still used today. Histologically, 
most breast tumors are classified into two major groups, these include invasive ductal carcinomas 
not otherwise specified (IDC-NOS) that make up 80% of breast cancers and develop from ductal 
cells, and invasive lobular carcinomas (ILC) that originate from milk producing glands (73). 
However, this histological classification system is very broad and there is debate over which type 
has a better prognosis. One study reported that patients with ILC are typically older, have well-
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differentiated estrogen receptor-positive tumors with reduced vascular infiltration, and have a 
better prognosis than IDC-NOS patients (74). Conversely, a later study demonstrated that there is 
no difference between the outcomes of patients with ILC and IDC-NOS (75). However, several 
rare IDC-NOS histologies have some prognostic value. For example, well-differentiated 
cribriform, tubular, and papillary carcinomas have good prognoses and typically do not require 
aggressive treatment (73,76-78). However, patients with poorly differentiated metaplastic 
carcinomas that contain spindloid, squamous, or lipid-rich features have poorer overall survival 
rates (73,79). 
 In addition to tumor histology analyses, specific tumor cell markers are also used to 
characterize breast cancers. These include estrogen and progesterone hormone receptors, and 
their expression can identify cancers that respond to endocrine therapies. Patients are 
considered for endocrine therapies when at least 1% of their tumor cells stain positive for 
estrogen or progesterone receptors. These patients typically do well in response to hormone 
receptor inhibitor treatments, and further chemotherapy is administered depending on lymph 
node status and levels of Ki67 proliferation marker staining (80-84). In addition, human epidermal 
growth factor receptor 2 (HER2) status is also taken into consideration during breast cancer 
evaluation. Tumors positive for HER2 can be treated with HER2 receptor inhibitors (82,85,86). 
Sadly, there are no targeted therapies for triple negative breast cancers, which are typically 
hormone receptor and HER2 negative. Therefore, further studies need to be performed to 
develop more effective treatments for patients with triple negative tumors. 
 Furthermore, Perou and colleagues demonstrated that microarray gene expression 
analysis could also classify breast cancer into distinct and clinically relevant subtypes. Based on 
their hierarchical clustering methodologies, at least five distinct tumor types were identified, 
including Basal-like, HER2-positive, claudin low, luminal A, and luminal B (70,71,87,88).  
The least aggressive of the molecular breast cancer subtypes is luminal A. The well-
differentiated histology status of most luminal A tumors correlates with this cancer’s typically good 
prognosis (78). Also, these tumors are hormone receptor positive and have luminal cell-specific 
gene expression patterns, which include hormone receptors and downstream targets, 
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transcription factors involved in luminal lineage commitment, and luminal cell specific cytokeratins 
(87,89). Due to their luminal-like nature, the growth of luminal A type tumors relies heavily on 
estrogen receptor signaling (90). In addition, these cancers frequently harbor mutations in the 
phosphatidylinositol-3-OH kinase (PI3K) and mitogen-activated protein kinase (MAPK) pathways, 
which may be important for noncanonical estrogen receptor signaling (89,90).  
 Another hormone receptor positive breast cancer with luminal cell features is luminal B. 
Although luminal B tumors share some gene expression patterns and mutations with luminal A 
subtypes, it is a much more aggressive cancer. Some factors that make luminal B cancers more 
aggressive include higher expression of proliferation markers, increased rate of mutations in the 
p53 tumor suppressor pathway, and higher overall histologic grade (88,89,91,92). Furthermore, 
these tumors do not respond well to endocrine therapies (93,94); however, potential inhibitors 
targeting components of the PI3K and epidermal growth factor receptor (EGFR) pathways are 
currently under investigation (95,96). 
Amplification of the tyrosine kinase receptor HER2 drives the growth of HER2-positive 
subtype tumors. HER2 signals by forming dimers with other EGFR family receptor tyrosine 
kinases, and activates downstream MAPK and PI3K pathways (97,98). As a result, much of the 
gene expression profile characterizing this molecular breast cancer class consists of downstream 
signaling components of the HER2 pathway (87,89). Furthermore, more recent gene expression 
analyses have also demonstrated that there may be two subclasses of HER2-positive cancers, 
one being estrogen receptor positive with luminal characteristics and the other having more basal 
features (89). HER2-specific inhibitors are available in the clinic (99-103); however, most patients 
with advanced disease relapse after treatment due to mutations in HER2, increased signaling 
through analogous receptor tyrosine kinase pathways, or loss of cell cycle control. Combination 
therapies targeting both HER2 and other parallel signaling components are currently under 
investigation (104). 
 Finally, triple negative breast cancers, which express the lowest levels of hormone 
receptors and HER2, have been classified into two molecular types. These include highly 
aggressive but closely related Basal-like and claudin low tumor classes (70,87). Overall, the 
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tumor morphology for these cancers is typically very metaplastic, with claudin low tumors 
frequently displaying a mesenchymal-like spindloid histology (70,78).  
The Basal-like breast cancer group is more specifically characterized by having similar 
gene expression and cytokeratin profiles as normal basal/myoepithelial cells (87). In addition, the 
majority of Basal-like tumors have p53 mutations, high PI3K pathway activation, and increased 
cell proliferation signatures (89). The Basal-like cancer group also includes tumors with 
inactivating mutations in the tumor suppressor breast cancer genes 1 and 2 (BRCA1 and 
BRCA2), which are important components of DNA damage repair complexes (89,105).  
The second triple negative breast cancer subtype consists of claudin low tumors that 
have a decreased expression of tight junction claudin and E-cadherin proteins. Furthermore, 
claudin low tumors upregulate genes involved in epithelial-to-mesenchymal transition and stem 
cell maintenance (50,70). Unfortunately, there are no targeted therapies for these highly 
aggressive Basal-like and claudin low breast cancers; therefore, further research needs to be 
performed to identify early detection markers and more specific treatments for these tumor types. 
 
The Tumor Cell of Origin Hypothesis 
Many cancers can consist of several distinct tumor subtypes that vary in clinical outcome. 
This intertumor heterogeneity can be explained by two different hypotheses: the mutation model 
proposes that accumulation of various genetic alterations define the tumor phenotype regardless 
of the initially transformed cell type (Figure 1.3A, adapted from Visvader, 2011 (106)), and the 
tumor cell of origin hypothesis proposes that the intrinsic properties or differentiation potential of 
the initially transformed cell population influence the resulting tumor phenotype (Figure 1.3B, 
adapted from Visvader, 2011 (106)). In addition, these two different hypotheses may not be 
mutually exclusive. 
Although both the genetic mutation and tumor cell of origin hypotheses may influence 
tumor heterogeneity, multiple lines of evidence suggest that specific populations of a tissue’s 
cellular hierarchy contribute to several distinct hematopoietic and solid cancer types. For 
example, hematopoietic stem cells harboring BCR-ABL mutations are the cells of origin of chronic 
myeloid leukemia (107,108). Also, more differentiated hematopoietic T-cell progenitors give rise 
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to T-cell acute lymphoblastic leukemia (109). Tumor cells of origin have also been identified in 
several solid tissue cancers. For instance, organ-specific stem cells give rise to intestinal and 
stomach cancers (110-113). However, various epidermal cell types contribute to distinct skin 
cancers: basal cell carcinomas can arise from interfollicular, infundibulum, and bulge cells; but 
squamous cell carcinomas originate specifically from bulge cells (reviewed in (114)). 
Furthermore, several studies suggest that different types of breast cancer may have specific cells 
of origin. 
Comparative gene expression analyses have demonstrated that there is a close 
relationship between distinct breast cancer subtypes and specific mammary epithelial cell 
populations. Basal and stem cells resemble the genetic profiles of claudin low tumors, whereas 
luminal progenitors are most closely related to Basal-like breast cancers. Furthermore, luminal A 
type tumors rely on the estrogen receptor signaling pathway for proliferation, and express high 
levels of differentiated luminal cell markers (70,87,88,115). These findings are correlative, but 
inherent tumor and cellular properties suggest that different breast cancers develop from specific 
populations of cells.  
Experimental evidence further supports the tumor cell of origin hypothesis in breast 
cancer. Ince et al., generated unique tumor types from two distinct mammary epithelial cell 
populations, demonstrating the transformed cell type influences cancer phenotype (116). In 
addition, the luminal progenitor population is proposed to be the tumor cell of origin of BRCA1-
mutant Basal-like breast cancers. This was initially shown by demonstrating that luminal, but not 
basal or stem cells, isolated from pre-neoplastic lesions of BRCA1 mutation carriers were 
predisposed to transformation (115). Then, later transgenic mouse mammary tumor models 
demonstrated that BRCA1-mutant luminal progenitors give rise to Basal-like tumors, whereas 
basal cells carrying the same mutation produce myoepitheliomas, which are rare in breast cancer 
(117). Further analyses need to be performed to determine if other breast cancer subtypes have 
a specific tumor cell of origin. Alternatively, it may be found that strong oncogenic drivers give rise 




Mouse Models of Breast Cancer 
 As discussed above, breast cancer is not a single disease, but consists of molecularly 
and pathologically diverse subtypes that require distinct treatment approaches. Experimental 
models that can recapitulate this heterogeneity are necessary in order to investigate the 
mechanisms driving disease progression. Such studies may lead to the discovery of more 
effective therapies for each breast cancer type. Over the past several decades, a variety of 
transgenic, mutagen-activated, and transplantation mouse mammary tumor models have been 
generated to achieve this goal. The purpose of this section is to provide an overview of several 
current mouse mammary tumor models, and to highlight their advantages and limitations in 
replicating breast cancer pathology. 
 
MMTV transgenic mouse models  
 The mouse mammary tumor virus (MMTV) is a murine retrovirus transmitted through 
lactation. MMTV can activate spontaneous mammary tumor growth in mice by disrupting host 
tumor suppressors or upregulating proto-oncogenes after insertional mutagenesis (118-121).  
MMTV promotes tumor growth predominantly in the mammary epithelium, due to the hormone 
responsive element in the long terminal repeat (LTR) of the MMTV promoter (122). Because of 
this high tissue specificity, several transgenic models have been developed using the MMTV 
promoter to drive oncogene expression in the mouse mammary gland (123-125).  
 One such oncogene is the polyoma virus middle T antigen (PYMT), and its expression 
through the MMTV promoter results in rapid mammary tumor growth in 100% of MMTV-PYMT 
transgenic mice (125,126). PYMT drives tumorigenesis by acting as a membrane-anchored 
scaffold for several cellular kinases and GTPases. This interaction leads to activation of Rat 
sarcoma (RAS) and protein kinase B (AKT) signaling pathways, followed by rapid cellular 
transformation (Figure 1.4, adapted from Rodriguez-Viciana et al., 2006 (127)) (128). The 
advantage of the PYMT oncogene is that it activates similar pathways that are misregulated or 
mutated in most breast cancers (89). Furthermore, progression of MMTV-PYMT tumor growth is 
similar to breast cancer. MMTV-PYMT tumor development begins with hyperplastic mammary 
epithelial lesions that invade into the ductal lumens and fat pad tissue. As tumors progress, they 
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gradually lose cellular organization and hormone receptor expression. At later stages, metastases 
occur in the lungs (129). Although MMTV-PYMT mice give rise to very predictable tumor 
pathologies, this model does not fully recapitulate the disease heterogeneity observed in breast 
cancer. A majority of MMTV-PYMT tumors consist of solid adenocarcinoma histology with luminal 
gene expression profiles (71,129). 
 To model HER2-positive breast cancer, the MMTV promoter has also been used to 
express the activated or wildtype rat homolog of HER2 (Neu) in the mouse mammary gland 
(98,130,131). Interestingly, when wildtype Neu is expressed, it frequently acquires activating 
mutations, resulting in more potent tumor growth (132-134). Similarly, HER2 amplifications and 
mutations that lead to receptor dimerization and activation are also observed in the human 
disease (134-138). These studies have helped to confirm that HER2 dimerization and activation 
drives tumor growth in HER2-positive breast cancers. Furthermore, just like the human 
counterpart, MMTV-Neu tumors are highly aggressive and frequently metastasize to the lungs 
(125). One drawback of this model is that unlike in breast cancer, MMTV-Neu tumors are very 
homogenous and molecularly luminal (71). MMTV promoter activity in subsets of luminal cell 
populations may contribute to this luminal tumor characteristic (53); however, the tumor cell of 
origin for HER2 breast cancer is yet to be defined.  
 The MMTV promoter has also been used to express Wnt1 (139). Wnt1 is a key 
component of the Wnt pathway that is involved in stem cell maintenance and proliferation through 
the activation of the β-catenin transcription factor (140,141). Tumors develop in about 50% of 
MMTV-Wnt transgenic mice within six months post birth, and typically display differentiated acinar 
histologies (139,142,143). Also, metastases frequently develop in lymph nodes and lungs after 
primary tumor excision, indicating that metastatic seeding occurs early during primary tumor 
growth (139). Unlike the other MMTV mammary tumor models discussed above, MMTV-Wnt 
tumors are molecularly basal (71). These findings suggest that activation of Wnt signaling may 
drive basal breast cancer development, possibly due to expression of genes involved in stem cell 
maintenance. Interestingly, increased nuclear localization and activity of β-catenin is detected in 
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high percentages of breast cancers, and is associated with aggressive disease and poor clinical 
outcomes (144-147).  
 Despite the vast application of the MMTV promoter in generating transgenic mouse 
mammary tumor models, some limitations of these models should be emphasized. Although, 
MMTV is primarily active in the mammary epithelium, MMTV can also drive gene expression in 
lungs, kidneys, salivary glands, seminal vesicles, T cells, testes, and prostate (148,149). 
Therefore, care needs to be taken in examining metastases at secondary tumor growth sites. 
Furthermore, as stated above, MMTV is active in subsets of hormone-responsive luminal cells 
and not all mammary epithelial cell types (53); as a result, MMTV driven tumors may not 
represent the vast tumor heterogeneity observed in breast cancer. It should be noted, however, 
that expression of different oncogenes using the MMTV promoter does promote the growth of 
distinct tumor types. These findings indicate that the oncogene plays a role in influencing tumor 
subtype. 
 
WAP transgenic mouse models 
 The whey acidic protein (WAP) promoter is regulated by lactogenic hormones and is 
primarily active in the mammary luminal epithelial cells during mid-pregnancy (51,150). Similar to 
MMTV, the mammary epithelial tissue specificity of this promoter has made it a useful tool in 
generating tissue-specific transgenic mouse mammary tumor models. Several oncogenes have 
been expressed using the WAP promoter to assess their ability to drive mammary tumorigenesis. 
 One of these is the c-myc protooncogene (MYC). MYC is a multifunctional transcription 
factor that is required during development and regulates many cellular processes, including 
apoptosis, proliferation, and metabolism (151,152). Mutations and amplifications of MYC have 
been reported in multiple malignancies, including breast cancer (153-157). In addition, recent 
studies show that luminal B and Basal-like breast cancers have the highest rates of MYC 
amplification and pathway activity (89). MYC expression in the mouse mammary gland under the 
control of the WAP promoter results in mammary tumors after two rounds of pregnancy in 80% of 
mice (158). However, unlike Basal-like breast cancer, WAP-MYC tumors typically consist of solid 
adenocarcinomas histology with a luminal molecular profile (71,158). 
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 The WAP promoter has also been used to express oncogenes driving tumor growth 
through similar mechanisms that are misregulated in breast cancer. These include int3, which is a 
truncated form of Notch4, and the Simian Virus (SV) 40 T antigen (TAg) (159,160). Int3 was 
initially identified as a frequent integration site for the murine retrovirus MMTV that led to 
spontaneous tumor growth (161); and TAg transforms cells by inhibiting p53 and retinoblastoma 
protein (pRB) tumor suppressor pathways (162,163). While WAP-Int3 tumors predominantly 
display solid adenocarcinoma histology, WAP-TAg mice give rise to histologically diverse tumor 
types (159,164). In addition, both of these models give rise to molecularly luminal tumors (71). 
In sum, the hormone responsive WAP mouse mammary tumor models have similar 
limitations as MMTV transgenic mice. WAP promoter expression is mammary gland selective; 
however, it also has some activity in other tissues (165). Furthermore, WAP models are limited in 
their ability to activate transgene expression in all mammary epithelial cell types, possibly 
contributing to the strictly luminal molecular tumor profiles observed in WAP transgenic mice 
(51,71). Therefore, WAP mammary tumor models do not recapitulate the tumor diversity 
observed in breast cancer (71). However, expression of different oncogenes using the WAP 
promoter does demonstrate that distinct oncogenes influence tumor subtype. 
   
BRCA transgenic mouse mammary 
tumor models 
As discussed in an earlier section, BRCA1 and 2 proteins are critical components of DNA 
repair machinery (89,105), and mutations in these genes are associated with high rates of familial 
breast and ovarian cancers (166). In addition, breast tumors harboring BRCA mutations are 
typically Basal-like and have a poor prognosis (87,88). Therefore, several transgenic mouse 
models have been developed to study BRCA mutations in the mouse mammary gland (117,167). 
Initially, investigators observed that germline deletion of BRCA1 results in embryonic 
lethality due to lack of sufficient cellular proliferation (168-170); therefore, LoxP-flanked 
conditional BRCA1 knockout mice were generated (171-175). Deletion of BRCA1 in the 
mammary epithelium was then achieved by breeding BRCA1 conditional knockouts with WAP 
and MMTV-Cre mice; however, it was found that additional mutations in p53 were necessary for 
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efficient tumor growth (175,176). These results demonstrated that other mutations in tumor 
suppressors might be necessary to drive BRCA1-mutant breast cancer progression.  
Also, since BRCA1-mutant breast cancers have a basal molecular profile (87), it was 
hypothesized that the basal progenitor population may be the tumor cell of origin for these 
cancers. To test this, the basal K14 promoter was used to target BRCA1 and p53 loss to the 
basal mammary epithelium. The resulting tumors closely modeled the human disease counterpart 
with their high proliferation profiles, poor histological grades, ER loss, and genomic instability 
(171). These results suggested that BRCA1-mutant Basal-like breast cancers originate from 
basal cells. 
Conversely, a more recent study demonstrated that the luminal progenitor population is 
the tumor cell of origin for BRCA1-mutant Basal-like breast cancer. In this study, Molyneux et al. 
used cell-specific Cre drivers to delete BRCA1 in mouse luminal or basal mammary progenitors. 
The histologic and molecular profiles of luminal cell-derived tumors closely resembled Basal-like 
breast cancers. Basal progenitors, on the other hand, gave rise to myoepitheliomas, which are 
rare in breast cancer (117). This study was different from the preceding reports, in that BRCA1 
was deleted in a p53 heterozygous background. Molyneux et al. argue that there is cooperation 
between complete loss of p53 and BRCA deletion in previously reported models, resulting in a 
Basal-like tumor phenotype originating from basal progenitors (171,177); however, the p53 
heterozygous background may be a more accurate model of BRCA-mutant Basal-like breast 
cancer. As discussed in a previous section, analyses of primary preneoplastic breast tissues 
support the hypothesis that the luminal progenitor is the cell of origin for BRCA-mutant Basal-like 
breast cancer (115). However, since mammary epithelial stem cell and progenitor compartments 
are heterogeneous (38), further studies need to be performed to assess how many different 
populations have the capacity to give rise to BRCA-mutant Basal-like breast cancer. Furthermore, 
p53 loss of function is highly associated with Basal-like breast cancer (89); therefore, potential 






DMBA mouse mammary tumors 
 7, 12-Dimethylbenz(a)anthracene (DMBA) is a polycyclic aromatic hydrocarbon that has 
been used as a carcinogen in many laboratory animals (178). DMBA interacts with and activates 
the cytosolic aryl hydrocarbon receptor (AHR); this leads to AHR cofactor binding and 
translocation into the nucleus (179,180). In turn, AHR acts as a transcription factor that promotes 
the expression of genes that metabolize DMBA into DNA binding compounds that lead to DNA 
damage and cellular transformation (181,182). In addition, AHR activity has been shown to 
regulate mechanisms of cellular proliferation and survival, which may further contribute to tumor 
growth (183-187). Therefore, administration of DMBA to mice can be used to generate mammary 
tumors (178). 
 About 75% of mice treated with DMBA develop mammary tumors; however, tumors in 
other tissues such as lungs, skin, and blood can also occur in 5-30% of mice. Therefore, care 
needs to be taken when examining metastases. Histologically, the DMBA-induced mammary 
tumors are fairly metaplastic and primarily squamous, but tubular, spindloid, papillary, and acinar 
tumors can also form (188). In addition to this histologic diversity, the molecular profiles of DMBA 
tumors are heterogeneous, but most tumors fall into the basal subtype (71). Due to this tumor 
diversity, this model does represent some of the heterogeneity observed in breast cancer; 
however, factors that drive tumor propagation can vary.  
 
Transplantation mouse mammary 
tumor models 
 As discussed in a previous section, the major mammary gland developmental events 
take place after puberty (1). Because of this, the mammary fat pad can be “cleared” of epithelial 
cells prior to puberty, and transplanted primary mammary cells can be used to regenerate 
functional ductal trees (189). Taking advantage of this, Welm et al. demonstrated that gene 
expression could be specifically targeted to the mammary epithelium by lentiviral infection of 
primary cells prior to transplantation (190). 
Smith et al. used this lentiviral infection and transplantation approach to express the 
PYMT oncogene in all mammary epithelial cell populations. Interestingly, this study demonstrated 
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that PYMT can give rise to molecularly and histologically diverse tumor types, recapitulating the 
disease heterogeneity observed in breast cancer. Unlike the MMTV-PYMT tumor model, the 
lentiviral approach demonstrated that expressing the same oncogene in diverse populations of 
cells results in diverse tumor phenotypes (191). This suggests that the tumor cell of origin may 
play a key role in influencing tumor subtype.  
 
Summary 
 Overall, transgenic mouse mammary tumor models are limited in their ability to 
recapitulate the broad molecular and histological heterogeneity observed in breast cancer (71). 
However, transgenic mice such as MMTV-PYMT and MMTV-Wnt do demonstrate that expression 
of different oncogenes under the control the same promoter can lead to the development to 
distinct tumor types (71). Therefore, oncogenes and mutations may play a role in defining breast 
cancer phenotype. Despite these findings, it is still unclear whether the tumor cell of origin can 
also influence tumor subtype. Unfortunately, current transgenic mouse mammary tumor models 
cannot be used to target oncogene expression to the full spectrum of mammary epithelial cell 
types, in a cell lineage restricted context. Due to this limitation, the purpose of the work described 
in this dissertation was to develop new methodologies that could test the tumor cell of origin 
hypothesis.  
The following chapters discuss a series of alternative approaches to transgenic mouse 
mammary tumor models, which utilize lentiviral infection and primary cell transplantation 
techniques to transform specific mouse mammary epithelial cell populations. Using these 
lentiviral infection and transplantation techniques, we were able to test whether the transformation 
of specific mammary epithelial cell populations influences breast cancer subtype. 
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Figure 1.1. Mammary gland development. The mammary epithelium develops during several key 
postembryonic stages, including puberty, pregnancy, and lactation. Specific growth factors and 
hormones regulate the initiation and progression of each mammary epithelial developmental 







































Figure 1.2. Mouse mammary gland epithelial cell organization and hierarchy. A. The mouse 
mammary gland is composed of a branched epithelial ductal network surrounded by a fat pad. 
The ducts are bilayered, consisting of luminal, basal, and stem cell populations. B. The mammary 
epithelial cell hierarchy consists of fetal and adult stem cells, lineage committed progenitors, and 






















































Figure 1.3. The molecular and pathophysiological heterogeneity observed in breast cancer may 
be explained by the genetic mutation and the tumor cell of origin hypotheses. A. The genetic 
mutation hypothesis proposes that different oncogenic evens in the same population of cells may 
contribute to different tumor phenotypes. B. The tumor cell of origin hypothesis proposes that the 
intrinsic properties of the initially transformed cell population may influence tumor phenotype. This 

































Figure 1.4. PYMT drives tumorigenesis by acting as a membrane-anchored scaffold for activation 
of RAS and AKT signaling pathways. First, Src family tyrosine kinases phosphorylate PYMT at 
tyrosines 250 and 315. This creates binding sites for upstream components of RAS and AKT 
pathways. In turn, activation of RAS and AKT leads to rapid cellular transformation and tumor 
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 The purpose of this manuscript was to test whether transformation of enriched mouse 
mammary epithelial cell populations influences tumor subtype and pathophysiology. This was 
achieved by combining lentiviral infection, fluorescence activated cell sorting, and transplantation 
techniques. Our results demonstrated that expression of the Polyoma Middle T Antigen oncogene 
within different mammary epithelial cell populations influences tumor histology, molecular 













Breast cancer is a multifaceted disease, exhibiting significant molecular, histological, and 
pathological diversity. Factors that impact this heterogeneity are poorly understood; however, 
transformation of distinct normal cell populations of the breast may generate different tumor 
phenotypes. Our previous study demonstrates that the polyomavirus middle T antigen (PYMT) 
oncogene can establish diverse tumor subtypes when broadly expressed within mouse mammary 
epithelial cells. Herein, we assess the molecular, histological, and metastatic outcomes from 
distinct mammary cell populations transformed with PYMT. 
 
Methods 
Isolated mouse mammary epithelial cells were transduced with a lentivirus expressing 
PYMT and sorted into hormone receptor positive luminal (CD133+), hormone receptor negative 
luminal (CD133-), basal, and stem cell populations using the cell surface markers CD24, CD49f, 
and CD133. Each population was subsequently transplanted into syngeneic cleared mouse 
mammary fat pads. Tumors were classified by histology, estrogen receptor status, molecular 
subtype, and metastatic potential to investigate whether transformation of different enriched 
populations affects tumor phenotype. 
 
Results 
While enriched mammary epithelial cell populations showed no difference in the ability to 
form tumors or tumor latency, differences in prevalence of solid adenocarcinomas, squamous, 
papillary, and sebaceous-like tumors were observed. Interestingly, both molecularly Basal and 
Luminal tumors developed from luminal CD133+, basal, and stem cell populations; however, 
luminal CD133- cells gave rise exclusively to molecularly Basal tumors. Tumors arising from the 
luminal CD133-, basal, and stem cell populations were highly metastatic; however, luminal 
CD133+ cells generated tumors that were significantly less metastatic, possibly due to an inability 





By combining several methodologies, including lentiviral infection, cell sorting, and 
transplantation, we have characterized tumors arising from enriched populations of mammary 
epithelial cells. We have found that expression of PYMT within different cell populations 
influences tumor histology, molecular subtype, and metastatic potential. 
 
Introduction 
Breast cancer can be classified into several distinct molecular and histological subtypes. 
These classifications provide important data which help guide patient therapy and predict 
outcome (1,2). Understanding how different breast cancer subtypes arise, and their cellular 
etiology, may improve strategies for detection, treatment, and prevention of the disease.  
Several studies support the concept that the tumor cell of origin plays a role in 
establishing the histological and molecular heterogeneity observed in breast cancer. For 
example, molecular markers that distinguish basal and luminal cell layers of the normal breast 
can also be used to differentiate Basal-like and Luminal breast cancer molecular subtypes.  
Tumors classified as the Luminal subtype express estrogen receptor (ER) and are generally 
dependent on estrogen for growth, recapitulating characteristics of a subset of normal, luminal 
epithelial cells found in the breast. In contrast, Basal-like breast cancer expresses molecular 
markers associated with basal epithelium. Furthermore, molecular signatures derived from 
normal mammary cell populations correlate with signatures from some tumor subtypes. For 
example, spindloid and claudin-low tumors exhibit molecular signatures associated with normal 
breast stem cells (3-5). Even differentiated mammary epithelial cells can share molecular features 
with cancer subtypes, as tumors histologically classified as lipid-rich carcinoma of the breast 
express metabolic and differentiation markers observed in alveolar cells (6-8). Given these 
similarities between normal and transformed cells, it is possible that transformation of distinct cell 
types in the mammary gland contributes to unique tumor phenotypes.  
Several studies have demonstrated that cancer phenotype is coupled, to some extent, 
with the cellular origin of the tumor. Ince et al. used different cell culture conditions to enrich for 
BPEC (luminal-like) and HMEC (myoepithelial-like) human breast cell populations. Each 
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population was subsequently transformed with a common set of oncogenic drivers and, when 
transplanted, they established distinct tumor phenotypes that included differences in tumor 
histology and metastasis (9). In addition, disparities in tumor phenotype were observed when 
BRCA1 loss-of-function was targeted to luminal cells versus basal cells (10). These studies 
suggest that intrinsic differences between cell populations may influence the histopathology of the 
tumor’s they generate.  
The polyomavirus middle T antigen (PYMT) oncogene has been used extensively in mice 
to model breast cancer. In these models, PYMT drives transformation of mammary epithelial cells 
by signaling through pathways frequently perturbed in breast cancer, including Src, Ras, and 
PI3K (11-14).  In MMTV-PYMT transgenic mice, the expression of PYMT is restricted to a subset 
of hormone-responsive mammary epithelial cells, and tumors that arise generally have features of 
luminal-like adenocarcinoma. This tumor phenotype may be influenced by the cell-lineage 
restricted expression of PYMT (3,15). In support of this, our previous work demonstrated that 
using a lentiviral approach to express PYMT broadly in all populations of the mammary epithelium 
permitted the development of molecularly and histologically diverse tumors [14]. The contrasting 
tumor phenotypes observed between these models may potentially be explained by differences in 
the cell type that expressed PYMT; a concept we explore herein.  
In the work presented here, we test whether different tumor phenotypes arise when 
specific mammary epithelial cell (MEC) populations are transformed with the PYMT oncogene. 
The results demonstrate that the precursor cell type does influence the prevalence of tumor 




FVB/NJ mice were obtained from The Jackson Laboratory and maintained in a pathogen-
free facility. Mice were handled according to University of Utah-approved Institutional Animal 





Generation of mouse mammary tumors 
 Freshly isolated MECs, collected from 8-10-week-old FVB/NJ mice, were infected with 
EF1-PYMT-ZsGreen lentivirus overnight at 37oC, as described previously (8). Following 
infection, cells were washed five times with Hanks Balanced Salt Solution (HBSS, Gibco) and 
incubated with 0.05% Trypsin-EDTA (Gibco) to isolate single cells. Trypsin was inactivated with 
MEC media (8), and cell clumps were removed by straining MECs through a 40μm cell strainer 
(Falcon). MECs were then re-suspended in wash buffer (HBSS+ 2% fetal bovine serum [FBS 
[HyClone]) and kept on ice for antibody staining and fluorescence activated cell sorting (FACS).  
Staining consisted of 6 tubes: 1) no antibody control, 2) CD24-V450 control, 3) CD49f-PE 
control, 4) CD133-APC control, 5) 7AAD control, 6) CD24-V450/CD49f-PE/CD133-APC/7AAD 
sample. During antibody staining, control tubes contained 5 X 104 cells and the sample tube 
contained 20 X 106 cells re-suspended in 200ul wash buffer. All antibodies were obtained from 
BD Pharmingen and were used at a 1:100 dilution. After adding the primary antibodies, cells were 
incubated on ice for 15 minutes. Following incubation, cells were washed with 1mL of wash buffer 
and centrifuged at 1000g for 2 minutes. Stained MECs were then re-suspended in wash buffer 
and sorted into luminal CD133+, luminal CD133-, basal, and stem populations as described 
previously (16-19), on a FACSAria-II SORP high-speed cell sorter, using FACSDiva Version 6.1.3 
software for analysis. Isolated MEC populations were kept on ice until transplantation. 
For each transplantation, 1 X 105 untransduced and unsorted MECs were mixed with 2 X 
104 transduced luminal CD133+, luminal CD133-, basal, or 5 X 103 stem-enriched MECs. MECs 
were then re-suspended in L Matrigel (BD Biosciences) per transplantation, and the Matrigel-
cell mixture was injected into the fourth cleared inguinal mammary fat pads of 3-week-old FVB/NJ 
mice. Tumor growth was monitored, and tumors were collected upon reaching 2 cm in diameter. 
Once tumors were harvested, viable cells were collected using the same protocol for MEC 
isolation, and then frozen in freeze media, as described previously (8). Portions of the tumors 
were also flash frozen for RNA isolation using the Qiagen RNeasy kit, and additional tumor 
fragments were processed for paraffin embedding.  
Infection, cell sorting, and transplantation experiments were performed over two rounds. 
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Each time, 10 transplants were performed per sorted MEC population, for a total 20 transplants 
per group. 
 
Antibody staining and histology 
 Portions of transduced and FACS-sorted MECs were used to quantify basal and luminal 
cell enrichment. For each isolated population 1 X 104 MECs, re-suspended in 200 L wash buffer, 
were centrifuged (Cytospin 4 Cytocentrifuge, Thermo Scientific) onto slides (Shandon Cytoslide, 
Thermo Scientific) at 900 rpm, for 10 minutes. Cytospun cells were then incubated with fix (4% 
paraformaldehyde in phosphate buffered saline [PBS]) for 15 minutes and washed 5 times with 
PBS for 5 minutes each. Fixed cells were permeabilized for 10 minutes with 0.2% Triton X-100 
(Sigma) in PBS, washed with 1% bovine serum albumin (BSA, EMD Chemicals) in PBS, and 
blocked with 1% BSA in PBS for 10 minutes. Cells were then incubated with primary antibodies 
against keratin 14 (K14, 1:400, rabbit, PRB-P-100, Covance) and keratin 8 (K8, 1:50, rat, Troma-
I, Developmental Studies Hybridoma Bank) for 1 hour at room temperature. Following incubation, 
slides were washed with 1% BSA in PBS and stained with 4',6-diamidino-2-phenylindole 
dihydrochloride (DAPI), and secondary antibodies Alexa Fluor 594 Chicken Anti-Rat IgG (1:1000, 
Invitrogen) and Alexa Fluor 488 Goat Anti-Rabbit IgG (1:1000, Invitrogen).  
Paraffin-embedded tumor samples were processed and analyzed by hematoxylin and 
eosin (H&E), ER immunohistochemistry (IHC), and cytokeratin staining, as described previously 
(8). The following primary antibodies were used: K14 (1:400, rabbit, PRB-P-100, Covance), K8 
(1:50, rat, Troma-I, Developmental Studies Hybridoma Bank), ER (1:200, Santa Cruz 
Biotechnology). Secondary antibodies included Alexa Fluor 594 Chicken Anti-Rat IgG (1:1000, 
Invitrogen), Alexa Fluor 488 Goat Anti-Rabbit IgG (1:1000, Invitrogen), and biotin-sp-conjugated 
(1:1000, Jackson ImmunoResearch). 
All immunofluorescent imaging was performed on an Olympus IX81 microscope using a 
Hamamatsu Photonics ORCA-ER camera. Fluorescent image recording and processing were 
performed using Slidebook 64 version 5.0.0.24. Slides processed for IHC and H&E staining were 
imaged on an Olympus Bx50 microscope with a Canon EOS Rebel XSI camera using EOS 
imaging software. Any changes in contrast and brightness were performed in Photoshop CS4 
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 Flash frozen tumors were randomly selected from each of the tumor groups for RNA 
extraction and microarray analysis. Total RNA was isolated using the Qiagen RNeasy kit. All 
steps of microarray processing, data filtering and normalization, and analysis were performed as 
described previously (8).  Batch adjustment was performed in two batches: dataset generated by 
Herschkowitz et al. was treated as one batch (Gene Expression Omnibus series GSE3165) [3], 
and data generated at the Huntsman Cancer Institute (HCI) was treated as a second batch. The 
HCI microarray dataset has been deposited in NCBI's Gene Expression Omnibus with the 
accession number GSE64453. 
 
Assessment of tumor metastasis 
 As described above, transplantation experiments were performed twice for each 
transduced and enriched MEC population. Lung metastasis for the first round was assessed by 
H&E staining; lung tissue processing and staining was performed as described above. Paraffin 
embedded lungs were serially sectioned at 10 m and every fifth slide was stained and examined 
for metastasis. For the second round of transplants, lung metastases were analyzed by 
fluorescent imaging after flattening the lungs between two glass slides. Slides were imaged as 
described above, and numbers of unique metastatic sites and tumor areas were quantified using 
ImageJ software. Prevalence of lung metastases and numbers of metastatic foci were consistent 
over two rounds of transplants. 
 To quantify circulating tumor cell (CTC) numbers, fresh whole blood was collected by 
cardiac puncture immediately after mice were euthanized according to University of Utah-
approved Institutional Animal Care and Use Committee procedures. CTCs were isolated for 
FACS analysis as described previously from mice bearing primary tumors, as well as no-tumor 
control mice (20). CTCs expressing ZsGreen were detected by analyzing cells using a FACScan 
cytometer (BD), and results were quantified using FlowJo Software (Treestar). Due to low 
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numbers of CTCs present within isolated whole blood, the ZsGreen-positive threshold was set at 
0.05% of no-tumor control background signal. This threshold was then used as a baseline for 
detecting CTCs in tumor-bearing mice. All CTC values were then normalized to no-tumor control 
background signal. 
 Tail vein injections were performed to assess the ability of tumor cells to colonize the lung 
after introduction into the bloodstream. Single cells were isolated from primary tumors using the 
same methodologies for as MEC isolation. Cells were then re-suspended in HBSS at 10 X 106 
cells/mL. 250 μL of the HBSS/cell mixture (2.5 X 105 cells) were injected into the lateral tail veins 
of 8-12-week-old FVB/NJ mice. Cells isolated from individual tumors were injected into five mice 
each. 20 days post injection, mice were sacrificed and tumor lung foci numbers were quantified 
by fluorescent imaging, using ImageJ software. 
 
Statistical analysis 
 All data analyses were performed using GraphPad Prism 6.0d software. For each 
analysis, specific statistical tests are indicated in the figure legends. P values are denoted by 
asterisks in the figures which represent the following values: * = p<0.05, ** = p<0.01, *** = 
p<0.0005, **** = p<0.0001. 
 
Results 
FACS-enriched mammary cell populations expressing PYMT develop  
tumors with equivalent latency 
Using a multistep procedure (Figure 2.1A), we evaluated whether transformation of 
distinct, normal mammary cell populations would influence tumor progression and pathology. 
Freshly isolated primary MECs were infected with the EF1-PYMT-ZsGreen lentivirus (8), and 
then stained and sorted for the cell surface proteins CD24, CD49f, and CD133, which are 
markers known to delineate luminal, basal, and stem cell populations. In accordance with 
published studies, luminal, basal and stem cells were isolated based on their expression of CD49f 
and CD24 (Figure 2.1B) (16,17,19). The luminal cell population was further separated into 
hormone-receptor positive and negative fractions by expression of CD133 (herein called luminal 
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CD133+ and luminal CD133-, respectively) (Figure 2.1B) (18). We next verified that enriched 
populations contained the expected keratin markers by evaluating each population for the 
expression of luminal cell-specific K8 and basal cell-specific K14 by immunofluorescence (Figure 
2.1C) (21). As expected, at least 90% of cells within each group expressed the appropriate 
marker(s) (Figure 2.1D) (16-19). Interestingly, approximately 15% of luminal-CD133- cells and 
33% of enriched stem cells were positive for both K8 and K14, suggesting the presence of a 
multipotent progenitor population within these groups (22-25). Additional experimental replicates 
generated similar cytokeratin expression profiles (Supplementary Figure 2.1).  
To assess tumor formation and progression of each subpopulation, transduced luminal 
CD133+, luminal CD133-, basal, and stem cells were individually transplanted into cleared mouse 
mammary fat pads. Each enriched MEC population was co-transplanted with unsorted and 
untransduced MECs to minimize potential trans-differentiation effects (26). Tumors arose from 
each enriched-MEC population and no statistical difference in average tumor latency or tumor-
free survival was observed (Figure 2.1E), demonstrating that all enriched MEC populations have 
the capacity to undergo transformation and generate tumors.  
 
Enriched MEC populations establish tumors with broad histopathology 
We next analyzed the histology of tumors originating from each of the enriched MEC 
populations. We classified tumors by H&E staining and cytokeratin expression, and identified the 
following histologies: acinar, papillary, solid adenocarcinoma, squamous, lipid-rich, and 
sebaceous-like (Figures 2.2A-F, Table 2.1). The frequency of a specific histology was quantified 
by estimating its area in 2-3 different sections per tumor (Figure 2.2G-K). Several trends became 
apparent. First, while papillary features were observed in all tumor origins, they were significantly 
enriched in tumors arising from luminal CD133+ cells as compared to the stem-enriched 
population. Next, the predominant histology generated by luminal CD133- cells was solid 
adenocarcinoma, while basal- and stem-enriched populations established more squamous 
tumors. Finally, several rare tumor types originated from specific MEC populations. Lipid-rich 
tumors arose primarily from the luminal CD133+ cell population, whereas sebaceous-like 
carcinoma developed primarily from basal and stem cells. Thus, each MEC-enriched population 
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generated tumors with a broad but distinct spectrum of histological subtypes. 
Estrogen receptor (ER) is a standard clinical marker used to guide a patient’s course of 
treatment and predict clinical outcome (27).  ER IHC staining was used to determine if any 
enriched MEC subgroups developed predominantly ER-positive (ER+) tumors, as defined by 
strong nuclear staining (Figure 2.2L). Surprisingly, all of the enriched MEC populations gave rise 
to ER+ tumors, and luminal CD133+ cells generated the highest proportion of ER+ tumors 
(Figure 2.2M). Interestingly, most of the ER+ tumors exhibited either papillary or acinar histology, 
whereas few squamous tumors stained positive for ER (Figure 2.2N). These observations are 
consistent with previous reports showing that ER+ status appears to be associated with well-
differentiated tumor histologies in PYMT-oncogene driven tumors, and is less prevalent in tumors 
that were poorly differentiated (28). 
 
Luminal CD133- MECs give rise to exclusively Basal subtype mammary tumors 
 We next wanted to determine whether MEC populations influenced the molecular 
classification of the tumors they generate. Tumors derived from each MEC population were 
classified by hierarchical analysis of microarray gene expression data.  This classification method 
has been used to group tumors from a variety of mouse models into Basal and Luminal subtypes, 
similar to those observed in breast cancer (3). We have previously demonstrated that lentiviral-
mediated expression of PYMT in unsorted MECs generates both Basal and Luminal tumor 
subtypes, which is in contrast to the development of only Luminal tumor subtypes in MMTV-
PYMT transgenic mice (3,8,15). We analyzed between 6 and 11 tumors generated from each 
enriched MEC population by microarray gene expression profiling and hierarchical clustering. We 
used an intrinsic 669-gene set consisting of genes differentially expressed in molecularly Basal 
and Luminal tumors to determine the molecular subtype (3). Gene set expression data were 
hierarchically clustered with 12 mouse models of breast cancer. Based on this analysis, we found 
that luminal CD133+, basal, and stem-enriched MECs were able to give rise to both Basal and 
Luminal tumors (Figure 2.3), with no correlation to tumor histology or ER status (data not shown). 
In contrast, the luminal CD133- population, which is enriched in luminal progenitors (18), 
exclusively established tumors of the Basal subtype. To determine the significance of this 
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observation, we compared the distribution of Basal and Luminal subtypes generated from each 
cell population with the distribution we observed when unsorted MECs were transduced with the 
PYMT lentivirus [8].  Only the luminal CD133- cells established tumors with a significantly 
different distribution of Basal and Luminal subtypes (p=0.017, Supplementary Table 2.1).  This 
finding was surprising, but not unprecedented, since luminal progenitors are proposed to be the 
cellular origin for Basal-like breast cancer observed in mouse models and patients carrying 
mutations in BRCA1 (4,10). These data further support luminal progenitors as a cellular origin for 
Basal-like tumors.   
 
Luminal CD133+ cells give rise to tumors that are significantly 
less metastatic than other tumor groups 
 We investigated whether the enriched MEC subgroups expressing PYMT generate 
tumors with different metastatic capacities. Similar to other PYMT-driven models, tumors 
generated from each MEC subgroup metastasized to the lungs (Figure 2.4A and Supplementary 
Figure 2.2A); metastasis to other organs was not detected. The metastatic burden in lungs was 
quantified by wholemount fluorescent imaging and H&E staining of serial lung sections. 
Interestingly, although no significant differences in tumor prevalence or progression were 
observed between the four tumor initiating populations (Figure 2.1D), tumors derived from the 
luminal CD133+ cell population were significantly less metastatic than all other tumor groups 
(Figure 2.4B). Furthermore, these cells formed significantly fewer lung tumor foci compared to the 
other tumor groups (Figure 2.4C); however, there was no difference in the average area per 
metastatic focus (Figure 2.4D). These data suggest that the cell of origin influences metastatic 
properties of a tumor. 
Metastasis progresses through several stages: cells leave the primary site and enter the 
bloodstream or lymphatics, survive within the circulatory system, exit the circulatory system, and 
colonize a secondary site (29). To identify differences in the metastatic process between tumor 
groups, we quantified circulating tumor cells (CTCs, a measure of tumor cell invasion and 
intravasation into the bloodstream) and assessed metastatic colony formation following systemic 
injection of tumor cells (a measure of tumor extravasation from the bloodstream, seeding, and 
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colonization at secondary sites). CTCs expressing fluorescent ZsGreen were quantified in whole 
blood from tumor-bearing mice by FACS and normalized to both the volume of collected blood 
and background fluorescence observed in non-tumor-bearing mice. Whole blood from mice with 
tumors derived from luminal CD133+ cells had significantly fewer CTCs than the other tumor 
groups (Figure 2.4E). However, when injected into the tail vein, both luminal CD133+ and CD133- 
tumor cells were able to colonize and proliferate within the lung regardless of whether the donor 
tumor was metastatic  (Figures 2.4F, Supplementary Figure 2.2B). These data suggest that 
luminal CD133+ cells give rise to tumors with a limited ability to escape the primary cancer and 
intravasate into the bloodstream.  
 
Discussion 
During transformation, a cell converts from a normal to a malignant state through a 
process requiring genomic and molecular alterations. A critical step is the activation of an 
oncogenic pathway, generally through genomic mutation, amplification, or overexpression. In the 
mammary gland, a transformed cell will originate within either the luminal or basal epithelium, 
where a spectrum of functionally distinct cell populations reside (30). Thus, tumorigenesis occurs 
within the unique molecular and cellular background of the cell of origin. How this affects the 
transformation process is not well understood; however, recent studies have demonstrated that 
the cellular context of a transforming event can affect characteristics of the tumor (9,10,31).  
Based on this understanding, we asked whether PYMT expression within different 
cellular origins of the mammary gland would affect histopathology, molecular subtype, and 
metastasis of tumors. In a previous study, we expressed PYMT broadly in mammary epithelium 
using a lentiviral approach, and compared the tumors with those derived from MMTV-PYMT 
transgenic mice (8). This comparison revealed significant differences in tumor histology and 
molecular subtype between the models. Mammary tumors derived from MMTV-PYMT mice 
exhibited a solid adenocarcinoma phenotype and were molecularly classified within the Luminal 
subtype (3,15). In contrast, tumors driven by the EF1-PYMT-ZsGreen lentivirus were 
histologically and molecularly diverse (8), thus demonstrating the PYMT oncogene has the ability 
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to generate a spectrum of tumor subtypes when it is broadly expressed in mammary epithelial 
cells.  
In the current study, we investigated whether expression of PYMT within specific cell 
populations alters the phenotypic outcome of tumors. The data demonstrate that each MEC 
population has the capacity to give rise to diverse tumor pathologies. However, some MEC 
populations did exhibit a prevalence of certain tumor types. Most striking was that luminal 
CD133+ cells gave rise to a higher proportion of tumors with papillary histology, ER+ expression, 
and limited squamous differentiation. Consistent with their well-differentiated pathology, tumors 
from luminal CD133+ cells also produced fewer CTCs and metastases. An opposing phenotype 
was observed in tumors generated by enriched stem cells. Notably, these cells gave rise to 
tumors that were ER negative (ER-), exhibited squamous differentiation, and produced more 
CTCs and metastases than luminal CD133+ cells. Thus, luminal CD133+ cells largely gave rise 
to well-differentiated tumors, whereas tumors derived from the enriched stem cell population were 
generally poorly-differentiated and metaplastic. These data are consistent with that reported by 
Keller et al., which showed that transformation of CD10-enriched human basal cells established 
ER- and metaplastic tumors with features of squamous differentiation (31). They proposed that 
the cellular precursor to metaplastic breast cancer resides within the basal cell layer, a hypothesis 
also supported by our study using a mouse mammary model. Taken together, these data 
demonstrate that tumor histopathology and metastatic potential are, at least partly, influenced by 
the tumor’s cellular origin. 
Mouse mammary tumor models can be molecularly classified by microarray gene 
expression profiling into Basal and Luminal tumor subtypes (3). It has been well established that 
tumors derived from MMTV-PYMT mice exhibit a Luminal subtype (3,15). In contrast, as we 
previously reported, targeting PYMT expression to all MEC populations, using a lentiviral 
approach, establishes both Basal and Luminal subtypes (8). Here we demonstrate that both 
Luminal and Basal tumor subtypes can arise from enriched luminal CD133+, Stem, and Basal 
mammary cell populations. However, we also show that transformation of CD133- luminal cells, 
which are enriched for luminal progenitors (18), generated only Basal tumor subtypes. This 
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finding was surprising and suggests luminal progenitors preferentially establish Basal rather than 
Luminal subtypes. However, this finding is consistent with several recent observations that 
attribute Basal-like breast cancer to a luminal progenitor population. Lim et al. demonstrated that 
the molecular profile of untransformed luminal progenitors most closely resembles Basal-like 
breast cancers (4). In addition, transformation of human EpCAM+/CD10-/CD49f+ luminal 
progenitors derived from reduction mammoplasties established tumors with features similar to 
Basal-like breast cancer, including reduced ER and greater CK14 expression than tumors derived 
from differentiated luminal cells (31).  Furthermore, targeting BRCA1 loss-of-function to luminal 
cells in mice generated tumors with Basal-like features that closely resemble those observed in 
patients carrying the BRCA1 mutation. However, the same loss-of-function in basal cells 
generated adenomyoepitheliomas (6,10). Taken together, these data support luminal progenitors 
as a potential cellular origin of Basal-like breast cancer. 
 
Conclusions 
We report that differentiated luminal (CD133+), luminal progenitor (CD133-), basal, and 
stem cell-enriched populations have the capacity to give rise to mammary tumors at equivalent 
frequency and latency when transformed with PYMT oncogene. However, mammary cell 
populations can produce tumors with differences in histopathology, molecular classification, and 
metastatic potential. Basal and stem cell-enriched populations predominantly established poorly 
differentiated squamous tumors, whereas differentiated luminal cells gave rise to a high 
proportion of estrogen receptor positive papillary tumors. We also demonstrate that the luminal 
progenitor-enriched population specifically gives rise to tumors with a Basal cancer molecular 
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Figure 2.1. A model to assess the influence of the cell of origin on tumor phenotype. A. Freshly 
isolated MECs were transduced with an Ef1-PyMT-ZsGreen lentivirus, FACS sorted into distinct 
populations, and transplanted into the cleared mammary fat pads of syngeneic mice. B. 
Transduced MECs were sorted into basal, luminal, and stem cell populations based on the 
expression of the cell surface markers CD49f and CD24 (right). Luminal cells were further sorted 
according to CD133 expression into hormone-receptor positive (CD133+) and negative (CD133-) 
populations (left). The collected populations are indicated by red gates. C. FACS-enriched 
populations were evaluated for expression of basal K14 (red), luminal K8 (green), and DAPI 
(blue) by immunofluorescence (scale bar: 20m). D. Quantification of the cytokeratin profile for 
each MEC subgroup (n: total number of cells imaged). E. Kaplan-Meier curves of mice receiving 
orthotopic transplants of distinct MEC subgroups. Mice were sacrificed when tumors reached 2-















































Figure 2.2. Analysis and prevalence of histology in tumors derived from MEC populations. A-F. 
Representative images of H&E and cytokeratin staining of tumor histologies: acinar (A), papillary 
(B), solid adenocarcinoma (C), squamous (D), lipid-rich (E), sebaceous-like (F). 
Immunofluorescence staining was performed for basal K14 and luminal K8 (scale bas: 100m).  
Histology area per tumor derived from luminal CD133+ cells (G), luminal CD133- cells (H), basal 
cells (I), and stem cells (J). K. Average area of histology per MEC group (unpaired t-test, n: 
number of tumors). L. Representative images of ER staining, including negative (left panel) and 
positive staining (right panel) (scale bar: 50m) (n: number of tumors). M. Quantification of ER 







































































Figure 2.3. Tumor microarray gene expression profiling. Tumors were analyzed by microarray 
gene expression profiling and hierarchically clustered with mouse mammary tumor models using 
an intrinsic gene set identified by Herschkowitz et al. 2007. Vertical lines indicate individial 
tumors. Each enriched MEC population is indicated by a different color: green: luminal CD133+;  
blue: luminal CD133-; red: basal; and, black: stem cells. Mouse mammary tumor models that 
generate molecularly luminal tumors are shown in dark blue, while those with predominatly basal 






































































































Figure 2.4. Metastatic profiles of tumors generated from enriched MEC populations. A. 
Representative DIC (left panel) and fluorescent (right) images of the same metastatic lung. 
Arrowhead indicated the same metastatic site. Black and white fluorescent images were false 
colored green in ImageJ and overlaid on a black background. ZsGreen expression is shown in 
green. B. Percent of mice with lung metastases per tumor group. Luminal CD133+ cell tumors 
were less metastatic than the other tumor groups (two proportion z-test; n: number of mice). C. 
Number of metastatic lung foci per tumor group. Luminal CD133+ cell tumors generated fewer 
metastatic foci than the other tumor groups (Mann-Whitney test, medians shown). D. 
Quantification of metastasis area per unique metastatic site in serial lung sections. No difference 
in tumor metastasis size was detected between the tumor groups (n: number of mice). D. 
Normalized number of circulating tumor cells in mice with luminal CD133+ tumors compared to all 
other tumor groups. ZsGreen signal in whole blood isolated from tumor-bearing mice was 
analyzed by FACS and normalized to no-tumor control signal. Luminal CD133+ tumor-bearing 
mice had fewer tumor circulating cells. Mice with nonmetastatic tumors are represented by green, 
and those with metastatic tumors are represented by black (unpaired t-test, means shown; n: 
number of mice). F. Quantification of the number of lung tumor foci per tail vein injection of 
metastatic luminal CD133+ tumor cells (Tumor 1), nonmetastatic luminal CD133+ tumor cells 
(Tumor 2), or metastatic luminal CD133- tumor cells (Tumors 3 and 4) (unpaired t-test, means 







































































Supplementary Figure 2.1. Robust enrichment of specific MEC populations. A. Transduced MECs 
were sorted into basal, luminal, and stem cell populations based on the expression of cell surface 
markers CD49f and CD24 (right). Luminal cells were further sorted according to CD133 
expression into hormone receptor positive (CD133+) and negative (CD133-) populations (left). 
Collected populations are indicated by red gates. B. FACS-enriched MEC populations were 
stained for basal K14 (red), luminal K8 (green), and DAPI (blue) (scale bar: 10m). C. 
















































































Supplementary Figure 2.2. Enriched MEC populations metastasize to lung. A. Representative 
image of H&E staining of a metastatic lung section. Arrow indicates metastasis (scale bar: 1mm).  
B.  Representative fluorescent lung images from mice that received tail vein injections of 
metastatic luminal CD133+ tumor cells (Tumor 1), nonmetastatic luminal CD133+ tumor cells 
(Tumor 2), or metastatic luminal CD133- tumor cells (Tumors 3 and 4). Lungs were examined 
three weeks after the tail vein injection. Fluorescent black and white lung images were false 
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Supplementary Table 2.1. Comparison of the distribution of Basal and Luminal tumor subtypes 
generated from each cell population with the distribution obtained from unsorted MECs [8], using 
Fisher’s exact test. 
Transformed population Basal subtype Luminal subtype P-value 
Luminal CD133+ 6 2 0.6757 
Luminal CD133- 11 0 0.0172 
Basal 5 2 1.0000 
Stem 4 2 1.0000 








TARGETING GENE EXPRESSION TO SPECIFIC MOUSE  
MAMMARY EPITHELIAL CELL POPULATIONS  




Breast cancer is a heterogeneous disease, which consists of diverse molecular and 
histological subtypes that vary in their clinical outcomes (1,2). Heterogeneity in breast cancer may 
be influenced by both the intrinsic factors of cancer cells, and extrinsic contributions of the 
tumor’s microenvironment and systemic hormones. Intrinsic factors include differences in 
molecular and genetic properties of the cell type that gave rise to the tumor, and genetic 
alterations that were acquired during tumor progression (3). While genetic alterations in cancer 
cells are known to be important effectors of tumor phenotype, recent studies are providing 
evidence that inherent factors of the cell from which the cancer originated can also influence 
tumor phenotype.  
Breast cancer can be divided into subtypes that are classified by the expression of 
specific molecular markers, many of which are associated with distinct mammary epithelial cells 
(MECs). For example, luminal breast cancers and normal luminal cells upregulate similar 
cytokeratins and hormone receptor pathways. The gene expression profiles of Basal-like breast 
cancers resemble those of normal luminal progenitors and basal populations. However, claudin-
low tumors express genes associated with stem cells (2,4-6). While these findings are correlative, 
they do suggest that some breast cancer subtypes may originate from distinct MEC populations.  
Experimental evidence further supports the hypothesis that distinct MEC populations give 
rise to specific breast cancer types. For example, Ince et al. generated unique tumor types from 
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two distinct mammary epithelial cell populations, demonstrating the transformed cell type 
influences cancer phenotype (7). Furthermore, several reports show that luminal progenitors are 
the origins of BRCA1-mutant Basal-like cancer (6) (8). Although informative, these studies were 
performed using in vitro approaches or a limited number of transgenic mouse mammary tumor 
models. As a result, it is still unknown whether other MEC populations give rise to specific tumor 
types. Therefore, more cell type-specific models are needed to identify the tumor cells of origin of 
other breast cancer subtypes. 
Many current transgenic mouse mammary tumor models utilize hormone-activated 
promoters to drive oncogene expression in the mammary epithelium. These include the mouse 
mammary tumor virus long terminal repeat (MMTV) and whey acidic protein (WAP) promoters (9-
11). MMTV and WAP transgenic mice have been used to successfully generate mammary tissue-
specific tumors, but these models fail to recapitulate the full molecular and histological tumor 
diversity observed in breast cancer (12,13). This may be due to the fact that WAP and MMTV 
promoters are primarily active in subsets of hormone-responsive luminal cells (13,14). However, 
the mammary gland epithelium consists of multiple cell types, including stem, basal, and luminal 
populations(15), and the MMTV and WAP promoters are unable to drive gene expression in all 
MEC types. Unfortunately, generating transgenic mouse mammary tumor models that can 
express a wide variety of oncogenes in specific MEC populations is difficult and not cost effective.  
As an alternative to generating transgenic mouse models, Welm et al. demonstrated that 
primary MECs can be transduced with a lentivirus expressing the enhanced green fluorescent 
protein (EGFP) under control of a ubiquitous elongation factor-1 alpha (EF1α) promoter. 
Subsequent transplantation of infected cells into the cleared mammary fat pads of recipient mice 
resulted in regeneration of functional mammary glands that expressed EGFP in all MEC 
populations, including luminal, basal, and stem cells (16). The benefit of this lentiviral infection 
and transplantation approach is that the lentivirus can be easily modified to express a wide 
variety of genes in the mammary epithelium; however, this model is limited in its ability to drive 
gene expression in a cell-specific manner. 
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Therefore, the aim of this chapter is to describe a protocol that combines lentiviral 
infection and transplantation techniques with Cre-mediated recombination to activate any gene 
expression in specific mouse mammary epithelial cell populations. In this approach, lentiviral 
constructs were designed to express a gene, oncogene, or fluorescent marker after Cre-mediated 
recombination. Next, MECs isolated from mice that express Cre under the control of lineage-
specific promoters were infected with the lentivirus. Transduced cells were then used for 
orthotopic transplantation for lineage tracing and tumor generation. Unlike the previous lentiviral 
and transgenic mouse mammary tumor models, this novel approach can be used to test the 
tumor cell of origin hypothesis by targeting oncogene expression to specific MEC populations.  
 
Results 
Lentiviral plasmid design  
and characterization 
Transgenic mouse models have extensively utilized Cre-mediated recombination at 
LoxP-flanked DNA regions to activate or suppress gene expression (17). As an alternative to 
generating a transgenic mouse model, we developed Cre-activated lentiviral constructs to target 
gene expression to cells with Cre recombinase activity. These constructs consist of a ubiquitous 
EF1α promoter (16) upstream of a LoxP-flanked translational stop cassette, which contains a 
histone H2B-fused enhanced green fluorescent protein (H2B-EGFP). To demonstrate that Cre-
expressing cells can be labeled using the lentiviral construct, a fluorescent Tomato reporter was 
inserted downstream of the stop cassette (Figure 3.1A). To transform Cre-expressing cells, the 
polyoma middle T antigen (PYMT) oncogene was inserted downstream of the stop cassette 
(Figure 3.1B). Thus, the lentiviral constructs were designed to express Tomato or PYMT after 
Cre-mediated recombination. 
The lentiviral plasmid encoding Tomato downstream of the LoxP-flanked stop cassette 
(henceforth termed LoxP-Tomato) was used as a reporter for Cre activity. To validate construct 
design, 293T cells were transfected with the LoxP-Tomato plasmid with or without a Cre-
expression plasmid (18). Fluorescence activated cell sorting (FACS) of plasmid-transfected cells 
demonstrated robust EGFP expression in LoxP-Tomato transfected cells, and Tomato was 
74 
expressed only after Cre-mediated LoxP recombination (Figure 3.1C). Because the translational 
stop cassette efficiently inhibited Tomato expression in the absence of Cre, the LoxP-Tomato 
lentivirus can be used to differentially label Cre-expressing cell populations. 
 The lentiviral construct encoding PYMT downstream of the LoxP-flanked translational 
stop cassette (henceforth termed LoxP-PYMT) was also validated by transfecting 293T cells with 
or without a Cre-expression plasmid (18). Western blot analysis demonstrates that HA-tagged 
PYMT protein was detected only in cells that expressed Cre (Figure 3.1D). Thus, the LoxP-PYMT 
lentivrus can be used to transform Cre-expressing cells. 
 Using the described letiviruses, specific MEC populations could be labeled with Tomato 
or transformed with the PYMT oncogene by infecting cells isolated from transgenic mice that 
express Cre under the control of population-specific promoters (several mammary cell-specific 
Cre lines are summarized in Supplementary Figure 3.1). Then, transduced cells could be grown 
in a three-dimensional matrix or transplanted into the cleared mammary fat pads of syngeneic 
mice for analysis (Figure 3.1E).  
 
Targeting gene expression to 
luminal MECs 
Because MMTV-Cre transgenic mice efficiently express Cre in the mammary gland 
epithelium (11), MECs isolated from these mice were used to characterize the lentiviral system in 
vitro and in vivo. Prior to infecting MECs from MMTV-Cre mice, the cell population that expressed 
Cre was validated. MMTV-Cre transgenic mice are reported to express Cre in the luminal cell 
population (11,13). However, several studies show that the MMTV promoter is also active in other 
MEC lineages (19,20). These disparate findings may be attributed to differences in genetic 
backgrounds of transgenic mice or variable transgene insertion sites.   
To identify Cre positive cells, MMTV-Cre mice were crossed with a Cre reporter line. Cre 
reporter mice express membrane-targeted Tomato (mT) prior to Cre-mediated recombination, 
and membrane-targeted green fluorescent protein (mG) after recombination (mTmG) (21). In vitro 
three-dimensional (3D) analyses of cells isolated from MMTV-Cre;mTmG mice demonstrated 
GFP expression in luminal keratin 8 (K8)-positive cells, and not basal keratin 14 (K14)-positive 
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cells (Figure 3.2A and B). Similar results were observed after imaging whole mammary duct 
fragments isolated from MMTV-Cre;mTmG mice (Figure 3.2C and D). Based on these data, we 
concluded that our mice express Cre in luminal MECs. 
Next, to show that our lentiviral and transplantation system can be used to target gene 
expression to specific cell types, MMTV-Cre MECs were infected with the LoxP-Tomato lentivirus. 
Infected MECs were cultured in 3D and cytokeratin staining demonstrated Tomato expression in 
luminal K8 positive cells (Figure 3.3A), and not basal K14 positive cells (Figure 3.3B). 
Furthermore, similar results were observed after infected MMTV-Cre MECs were transplanted 
into the cleared mammary fat pats of syngeneic background mice: 93% of transplants gave rise to 
fluorescent outgrowths, and Tomato was expressed only in luminal K8 positive cells (Figures 
3.3C-F). Therefore, the described lentiviral system can target gene expression to MECs in a 
population-specific manner, and cells can be analyzed using in vitro and in vivo applications. 
It should be noted, however, that most of the LoxP-Tomato infected MEC outgrowths 
were singly labeled with Tomato, and only one outgrowth contained EGFP- and Tomato-positive 
cells (Figure 3.3C). This result may be due to the fact that only about 25-30% of cells get infected 
prior to transplantation (data not shown). It is possible that luminal cells may be more readily 
transduced than other MEC populations. As a result, most of the infected MMTV-Cre outgrowths 
were Tomato-positive. 
As a control, MECs isolated from FVB/NJ mice were infected with LoxP-Tomato and 
transplanted. This was done to test whether Tomato is expressed in the absence of Cre. Seven 
out of eight transplants generated fluorescent outgrowths, and all were singly labeled with EGFP 
(Supplementary Figure 3.1A). Confirming, that gene expression downstream of the LoxP-flanked 
stop cassette is inhibited in the absence of Cre. Furthermore, keratin staining of mammary duct 
fragments demonstrated that both luminal and basal populations could be infected 
(Supplementary Figures 3.2B and C). Additional studies need to be performed to determine why 
most of the MMTV-Cre outgrowths were singly labeled with Tomato, even though both basal and 
luminal populations were labeled in several control transplants. We did observe that fluorescent 
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outgrowths consisted of both infected and uninfected cells; therefore, the singly labeled MMTV-
Cre outgrowths are likely originating from a mixture of infected and uninfected cells.  
 
Targeting gene expression to basal  
and stem MECs  
 In addition to luminal cells, the mammary epithelium is composed of basal and stem cell 
populations (15). Therefore, our lentiviral system could also be used to target gene expression to 
these populations using MECs isolated from mice that express Cre under the control of basal and 
stem cell promoters. These include K14 and leucine-rich-repeat-containing G-protein-coupled 
receptor 5 (LGR5) promoters, which have been shown to activate Cre expression in mammary 
gland basal and stem cells, respectively (8). Furthermore, basal cells upregulate smooth muscle 
proteins as they differentiate into contractile myoepithelial cells (22). Therefore, smooth muscle 
22-alpha (SM22α) and smooth muscle myosin heavy chain (SMMHC) promoters may drive Cre 
expression in more differentiated basal myoepithelial cells (15,23,24).  
To test whether our lentiviral system can also be used to target gene expression to 
mammary basal and stem cells, MECs isolated from LGR5-CreER, K14-CreER, SMMHC-Cre, 
and SM22α-Cre mice were infected with LoxP-Tomato and cultured in 3D. As expected, Tomato 
reporter expression was detected in the basal and not luminal cell layer of K14-CreER, SMMHC-
Cre, and SM22α-Cre 3D mammary cell cysts (Figures 3.4A-C). In LGR5-CreER mammary cell 
3D cultures, Tomato localized to stem cells that sparsely populate the basal layer (Figure 3.4D) 
(25). These in vitro data demonstrate that our system can be used to deliver gene expression to 
multiple distinct mammary epithelial cell populations, including basal and stem cells. 
 
Transformation of luminal MECs 
 Next, we generated the LoxP-PYMT letivirus, to target oncogene expression to specific 
MEC populations. This lentivirus was developed to test whether specific MEC populations 
influence breast cancer phenotype. The PYMT oncogene was selected as the driver of cellular 
transformation because it activates similar pathways that are perturbed in breast cancer, 
including RAS and AKT (26,27).  
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Initially, to test whether luminal cells could be transformed using our lentiviral system, 
MECs isolated from MMTV-Cre mice were infected with LoxP-PYMT and transplanted. As a 
negative control, MECs isolated from FVB/NJ mice were also infected with LoxP-PYMT and 
transplanted. In both experiments, 1X105 transduced cells were transplanted per mouse. All 
MMTV-Cre MEC transplants gave rise to tumors with an average latency of 132 days. 
Surprisingly, we observed that 43% of FVB/NJ transplants also gave rise to tumors with an 
average latency of 142 days (Figure 3.5A). These tumors grew in the absence of any Cre 
recombinase activity (data not shown).  
To identify the mechanism driving tumor formation in the control mice, we sequenced the 
lentiviral DNA integrated into the genomes of transformed cells. Interestingly, all tested tumors 
exhibited homologous recombination at LoxP DNA regions (Figures 3.5B). The fact that tumors 
arose due to LoxP recombination in the absence of Cre in control transplants was surprising, but 
not unprecedented since examples of homologous recombination in transfected cells have been 
described. Rubnitz et al. demonstrated that homologous DNA plasmid sequences as little as 14 
bases could recombine in transfected cells (28).  Therefore, it is probable that some homologous 
recombination occurred at plasmid LoxP sites in cells that were transfected during the production 
of lentivirus, resulting in recombined lentiviral particles.  
As described in Figures 3.1, 3.3, and Supplementary Figure 3.2, inappropriate Tomato or 
PyMT expression was not detected during plasmid and lentivirus characterization. Therefore, 
homologous recombination in the absence of Cre was likely a rare event. This rare inappropriate 
recombination was detected only after potent PYMT oncogene expression. Fewer tumors with 
longer latencies from FVB/NJ cell transplants further suggest that the frequency of homologous 
recombination in the absence of Cre was rare.  
Unfortunately, due to this inappropriate recombination, we were unable to distinguish  
tumors that arose from cells expressing Cre and cells that did not express Cre. To resolve this, 
MECs isolated from MMTV-Cre;mTmG mice were used for LoxP-PYMT lentiviral infection and 
transplantation. As a result, tumors that arose from Cre recombination could be labeled with GFP, 
and tumors that arose from non-Cre mediated homologous recombination would be Tomato-
78 
positive. As a control, MECs isolated from mTmG mice were also infected with LoxP-PYMT and 
transplanted. Furthermore, to reduce the number of tumors arising from non-Cre-mediated 
recombination, 2.5x104 infected cells were transplanted per mouse. In fact, the lower number of 
transplanted cells decreased the number of tumors in control mice to 20%. The lower number of 
transplanted cells did not change the latencies of tumors generated from MMTV-Cre;mTmG 
mouse MECs (Figure 3.5A).  
The number of GFP and Tomato labeled tumors derived from mTmG and MMTV-
Cre;mTmG MECs was determined using FACS. We identified tumors that consisted of only 
Tomato- or GFP-positive cells, and tumors that consisted of a mixture of GFP- and Tomato-
positive cells (Figure 3.5C). As expected, all tumors derived from mTmG mouse MECs were 
Tomato-positive, demonstrating that these tumors arose from cells that do not express Cre 
(Figure 3.5D). Conversely, MMTV-Cre;mTmG mouse MECs gave rise to tumors consisting 
exclusively of GFP- or Tomato-positive cells, and tumors consisting of both Tomato- and GFP-
positive cells. These results show that MMTV-Cre;mTmG MECs generated tumors derived from 
Cre expressing cells, and cells that do not express Cre. Although we were unable to inhibit 
aberrant lentivirus recombination, using an mTmG Cre reporter system allowed us to identify 
tumors that arose from the expected MEC population.  
The ultimate goal of our mammary tumor model is to investigate whether different MEC 
populations contribute to the phenotypes observed in breast cancer. Tumor histology is one way 
to classify cancer subtype. Previous studies show that MMTV-PYMT transgenic mice typically 
develop solid adenocarcinomas (9). It is not clear, however, whether this phenotype is specific to 
PYMT-driven pathogenesis, or if the cell of origin targeted by the MMTV promoter preferentially 
gives rise to adenocarcinomas. In a recent study, Smith et al. reported that targeting expression 
of PYMT in a variety of MEC populations using a lentiviral approach resulted in diverse 
histopathology, dissimilar to what is observed in the MMTV-PYMT model. This study 
demonstrated that PYMT-driven pathogenesis does not inherently establish solid 
adenocarcinomas (29). To determine whether MMTV-expressing luminal cells preferentially give 
rise to solid adenocarcinomas, tumors derived from MMTV-Cre;mTmG and mTmG MECs were 
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examined by hematoxylin and eosing (H&E) staining. Most of the GFP-positive tumors derived 
from MMTV-Cre;mTmG MECs were solid adenocarcinomas with papillary and squamous regions 
(Figure 3.5J), while Tomato/GFP mixed tumors appeared to be much more heterogeneous. 
Overall, diverse histologies were identified, including solid adenocarcinoma, papillary, squamous, 
lipid-rich, and sebaceous-like (Figures 3.5E-I). Furthermore, several single tumor masses 
consisted of multiple histologies. Although these data suggest that solid adenocarcinomas may 
preferentially arise from luminal cells, more tumors need to be examined to ascertain the 
significance of these findings. 
 
Transformation of other  
MEC populations 
 Next, PYMT expression was targeted to other MEC populations by infecting cells isolated 
from K14-CreER;mTmG, SM22a-Cre;mTmG, SMMHC-Cre;mTmG, K8-CreER;mTmG, and 
LGR5-CreER;mTmG mice with LoxP-PYMT. Following infection, 2.5x104 cells were transplanted 
into the cleared mammary fat pads of syngeneic background mice to generate tumors. Tamoxifen 
was administered at two different time points to mice receiving transplants of CreER cells. One 
cohort of transplants received tamoxifen at 1 week post transplantation (WK1), the second cohort 
was dosed at 4 weeks (WK4). Tamoxifen administration at two different time points was 
performed with the aim of activating PYMT expression in either progenitor, or more differentiated 
MEC populations.  
Tumor latencies and numbers of mixed, Tomato-positive, or GFP-positive tumors are 
summarized in Table 3.1. Interestingly, tumors generated from LGR5-CreER;mTmG, K14-
CreER;mTmG, and SM22a-Cre;mTmG were primarily Tomato-positive; however, the frequency 
of these tumors was much higher than mTmG MEC-derived tumors. Further experiments need to 
be performed to determine whether some cell populations are resistant to transformation. In 







Discussion and Future Directions 
 This chapter describes a lentiviral infection and transplantation model that can be used to 
target gene expression to specific MEC populations. Our goal was to determine whether a 
lineage-targeted lentiviral approach may serve as a more accessible and versatile method than 
transgenic mouse models for studying genes involved in mammary gland development and 
pathogenesis.  
To validate our system, fluorescent Tomato was successfully targeted to the luminal 
lineage using the LoxP-Tomato lentivirus and MECs isolated from MMTV-Cre mice. Interestingly, 
most of the LoxP-Tomato infected and transplanted MMTV-Cre cells gave rise to singly labeled 
outgrowths. As expected, the outgrowths expressed Tomato in the luminal cell population, but 
EGFP expression was lost in most outgrowths. This result may be due to several reasons. For 
example, basal cells could be more resistant to lentiviral infection, or more luminal cells survived 
the infection and transplantation procedures. Fluorescent imaging of outgrowths generated from 
MECs that express Cre in basal populations may help answer this question. Also, FACS can be 
used to enrich the number of infected cells prior to transplantation, which may enhance the 
generation of double-labeled outgrowths. Despite these findings, which may not be important for 
in vitro and tumor studies, our data demonstrate that genes can be targeted to specific MEC 
populations using the described lentiviral system. 
Furthermore, we demonstrate that our lentiviral model can be used to transform specific 
MEC populations; however, tumors also arose due to inappropriately recombined lentivirus. 
Therefore, a Cre reporter is required to identify tumors arising from Cre expressing cells. These 
findings should be used as a caution for other investigators that utilize similar transduction 
techniques to generate tumors. For example, analogous to our lentiviral system, Marumoto et al., 
developed a series of Cre-loxP–controlled lentiviral vectors that express oncogenes downstream 
of a LoxP-flanked stop cassette. These lentiviruses were then used to generate a gliablastoma 
multiforme mouse model (30). In a later publication, Friedmann-Morvinski et al. used the same 
lentiviral system to demonstrate that neurons and astrocytes can de-differentiate and give rise to 
gliomas (31). Although the published findings may be valid, neither study reported a control 
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experiment in which mouse cells that do not express Cre were infected to see if tumors could be 
generated in the absence of Cre. Furthermore, an internal reporter system, such as mTmG, was 
not used to label tumors arising from cells that express Cre. Therefore, to avoid any potential 
aberrant tumor growth, it would be important to investigate whether a lentiviral oncogene delivery 
system is tightly regulated in all tissues prior to tumor analysis.  
Regardless of the caveats associated with our oncogenic lentiviral system, it can still be 
used for broad applications to investigate breast cancer pathogenesis. Several recent studies 
have demonstrated that the luminal progenitor population is likely the cell of origin for BRCA1-
mutant breast cancer (6,8,32). Other mutations frequently found in breast cancer may also 
preferentially lead to tumor development in distinct MEC populations. One benefit of our system is 
that our lentiviral constructs can be easily modified to express different oncogenic factors. For 
example, future studies can utilize our methodology to express activated Neu (33) in specific 
MEC populations to investigate whether HER2-postive breast cancers preferentially arise from 
distinct cell types. 
Finally, one way to improve the lentiviral model described in this chapter is by delivering 
the lentivirus directly to the mammary gland epithelium through nipple injection. The procedure of 
liquid injection into the nipples of mice has been described previously (34). Injecting lentivirus into 
the mammary gland through the nipple would eliminate the need for transplantation and reduce 
any potential side effects due to inflammation. Also, this approach will decrease the number of 
mice used, and lower the need for inbreeding to ensure that transplant rejection does not occur. 
We have had some success in delivering dye as well as lentivirus to the mammary epithelium by 
nipple injection; unfortunately, our results were inconsistent. Optimization of the injection 




All studies using mice were carried out in strict accordance with University of Utah IACUC 
guidelines. Surgeries were performed under isofluorane anesthesia, and all efforts were made to 
minimize animal suffering and prevent infection. Mice used for tumor surgeries were monitored 
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and euthanized once tumors reached 2cm in diameter. Mice were euthanized using carbon 
dioxide, followed by cervical dislocation. 
FVB/NJ (stock number 001800), LGR5-CreER (stock number 008875), K14-CreER 
(stock number 005107), SMMHC-Cre (007742), SM22α-Cre (stock number 004746), and mTmG 
(stock number 007576) mice were obtained from The Jakson Laboratory. MMTV-Cre mice were a 
generous gift form Tiffany Seagroves, University of Tennessee. K8-CreER mice were a generous 
gift from Li Xin, Baylor College of Medicine. All mice were backbred to FVB/NJ mice at least ten 
generations prior to performing transplantation experiments. 
 
Plasmid and lentivirus generation 
LoxP-Tomato and LoxP-PYMT lentiviral plasmids were generated over several cloning 
steps. First, Brittni Smith constructed a plasmid containing the EF1a-LoxP-H2B-EGFP-stop-LoxP 
sequence. To create the plasmid, the IRES and ZsGreen were removed from the previously 
described HIV-ZsGreen plasmid (plasmid # 18121, Addgene). An oligo was generated containing 
the LoxP sites along with a multiple cloning site (top oligo 
sequence: CCGGGAATTCATAACTTCGTATAATGTATGCTATACGAAGTTATGGATCCATGCAT
CCCGGGCCTAGGATAACTTCGTATAATGTATGCTATACGAAGTTATTCTAGACCGG, bottom 
oligo sequence: CCGGTCTAGAATAACTTCGTATAGCATACATTATACGAAGTTATCCTAGGCC 
CGGGATGCATGGATCCATAACTTCGTATAGCATACATTATACGAAGTTATGAATTCCCGG). 
The oligo was inserted using enzyme sites EcoR1 and Xba1 into the above backbone. Then, 
H2B-EGFP was PCR amplified from a previously described plasmid (plasmid #11680, Addgene) 
and ligated into the backbone using cut sites BamHI and NsiI. LoxP-Tomato and LoxP-PYMT 
lentiviral vector cloning was completed by PCR amplifying Tomato and PYMT from previously 
described plasmids (pHIV-dTomato [Addgene plasmid # 21374], EF1α-PYMT (29)). Then, the 
amplicons were inserted into the EF1α-LoxP-H2B-EGFP-LoxP backbone using NsiI and KpnI 
restriction sites. PYMT was amplified using a HA-tagged reverse primer. The LoxP-Tomato and 




Lentiviral plasmid validation 
The LoxP-Tomato and LoxP-PYMT lentiviral plasmids were tested by transfecting 293T 
cells with or without a Cre expression plasmid (pBS513 EF1alpha-cre, plasmid # 11918, 
Addgene) (18). First, 293T cells were grown to 90% confluence in a 10cm culture plate at 37oC, 
using 293T culture media (DMEM + 10% fetal bovine serum [FBS]). Transfections were 
performed after changing the 293T media and adding 1mL of Opti-Mem media (Invitrogen) with 
30µg polyethylenimine (Sigma), and 2.5µg of each plasmid DNA, per plate. The cells were 
allowed to incubate overnight at 37oC. The following day, the transfection media was removed 
and cells were cultured for 48 hours in 293T culture media prior to analysis. Then, cells 
transfected with the LoxP-Tomato lentiviral plasmid were analyzed by FACS using a FACScan 
cytometer (BD), and results were quantified using FlowJo Software (Treestar). Cells transfected 
with the LoxP-PYMT lentivirus were lysed and analyzed by western blot using standard Odyssey 
system protocols. Primary antibodies against HA (mouse, 1:500 dilution, Santa Cruz 12CA5) 
were used to detect the HA-tagged PYMT, and primary antibodies against actin were used as a 
loading control (rabbit, 1:1000 dilution, Abcam ab1801). Anti-rabbit IRDye800 and anti-mouse 
IRDye680 secondary antibodies were used (1:10,000 dilution, Li-Cor). The antibody staining was 
visualized using the Odyssey Infrared Imaging System (Li-Cor).  
 
In vitro 3D MEC culture  
 MECs were isolated from the mammary glands of 8-12-week-old Cre-expressing, mTmG, 
or FVB/NJ mice and frozen for storage as described previously (29). The same cell isolation 
protocol was used for all experiments using MECs. 
 To infect cells for 3D culture, MECs were thawed at 37oC and plated in monolayer at a 
concentration of 2.5 x 105 cells per well in a 6-well plate, in MEC media (29).  Thawed cells were 
allowed to adhere to the plate and recover overnight.  Then, MECs were infected with high tighter 
lentivirus with a multiplicity of infection of 30, overnight.  After infection, cells were washed five 
times with MEC media and trypsinized (0.05% trypsin/EDTA, Gibco). Single cells were 
transferred to a 24-well plate and were allowed to aggregate overnight in 1mL of MEC media. 
After aggregation, 500 MEC aggregates per 20µl Matrigel (BD Biosciences) were plated per well 
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in chamber slides (Millipore).  Then, cysts were allowed to grow in epidermal growth factor (EGF) 
MEC media (5µg/mL insulin, 2.5nM mouse or human EGF, 100U/mL penicillin-streptomycin, 
DMEM-F12) for 5-7 days. Media was changed every other day. When the majority of aggregates 
formed hollow cysts, 4% paraformaldehyde in PBS was used to fix the cultures for 30 minutes at 
room temperature. Then cells were washed five times, for 5 minutes each with PBS, and 
permeabilized with 0.05% Triton-X 100 in PBS, overnight at 4oC. Blocking was done overnight at 
4oC as well, using 3% BSA and 1% goat serum in PBS. Then, the cysts were stained with primary 
antibodies against K14 (1:400, rabbit, PRB-P-100, Covance) and K8 (1:50, rat, Troma-I, 
Developmental Studies Hybridoma Bank), overnight at 4oC in block solution. Secondary 
antibodies Alexa Fluor 594 Chicken Anti-Rat IgG (1:1000, Invitrogen) and Alexa Fluor 488 Goat 
Anti-Rabbit IgG (1:1000, Invitrogen) were incubated with the cysts overnight at 4oC in block 
solution. After washing the secondary antibodies off 5 times with PBS, cell nuclei were stained 
with 4',6-diamidino-2-phenylindole (DAPI), chambers were removed from the slides, and the 
Matrigel cultures were cover-slipped. All immunofluorescent imaging was performed on an 
Olympus IX81 microscope using a Hamamatsu Photonics ORCA-ER camera. Fluorescent image 
recording and processing were performed using Slidebook 64 version 5.0.0.24. 
 
MEC transplantation 
 To infect cells for transplantation experiments, MECs were thawed as described above 
and plated at a concentration of 2 x 106 cells per well in a low adhesion 24-well plate, in MEC 
media. Cells were immediately infected with high titer lentivirus with a multiplicity of infection of 5, 
overnight. Following infection, cells were washed five times with MEC media and kept on ice until 
transplantation. For MECs infected with LoxP-Tomato lentivirus, 1 x 105 cells were mixed with in 
10µl of Matrigel (BD Biosciences) and injected into the fourth cleared inguinal mammary fat pads 
of 3-week-old FVB/NJ mice.  For MMTV-Cre and FVB/NJ MECs infected with LoxP-PYMT 
lentivirus, 1 x 105 cells were mixed with 10µl of Matrigel (BD Biosciences) and transplanted per 
mouse as described above. And for all MECs from mice that were bred with the mTmG Cre 
reporter, infected with LoxP-PYMT lentivirus, 2.5 x 104 with 10µl of Matrigel (BD Biosciences), 
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and transplanted per mouse as described above. Tamoxifen was administered at two different 
time points to mice receiving transplants of CreER cells infected with the LoxP-PYMT letivirus. 
5mg of tamoxifen (Sigma) dissolved in sesame oil (Sigma) was delivered through oral gavage, 
three times, once every other day. One cohort of transplants received tamoxifen at 1 week post 
transplantation (WK1), the second cohort was dosed at 4 weeks (WK4).  
 
Mammary outgrowth and  
tumor analysis 
 LoxP-Tomato lentivirus infected MEC transplants were allowed to generate mammary 
outgrowths for 8 weeks. After 8 weeks, mammary glands were harvested, compressed between 
two glass slides, and imaged on a fluorescent dissecting scope. After imaging, tissues were 
dissociated as described previously [21], but were not trypsanized to single cells in order to 
preserve ductal structure for later staining and imaging. Next, organoids were embedded in 
Matrigel (BD Biosciences), fixed, stained, and imaged using the same methodology as the in vitro 
3D MEC cyst culture experiments. 
 LoxP-PYMT lentivirus infected MEC transplants were allowed to grow into tumors until 
2cm in diameter. Portions of the tumor tissues were flash frozen for later DNA and RNA 
extraction, fixed in 4% paraformaldehyde for later histology analysis, and dissociated to organoids 
and single cells for freezing, as described previously [21]. 
 To amplify and sequence integrated lentiviral DNA in tumors generated with the LoxP-
PyMT lentivirus, DNA was isolated from flash frozen tumor tissue using a Qiagen Dneasy Blood 
and Tissue Kit. PCR was performed on the isolated genomic DNA using the following primers: 5’-
TATCCAGCACAGTGGCGG-3’ (forward primer) and 5’-TTCTCCAGCAGTATGTGCG-3’ (reverse 
primer). The PCR products were excised from an agarose gel using a Qiagen MinElute Gel 
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Figure 3.1. Plasmid characterization and description of model. A. LoxP-Tomato lentiviral construct 
and Cre-mediated recombination. B. LoxP-PYMT lentiviral construct and Cre-mediated 
recombination. C. The LoxP-Tomato lentiviral construct expresses Tomato only after Cre-
mediated recombination. Cells were transfected with LoxP-Tomato plasmid alone (left) or with the 
addition of a Cre-expression plasmid (right) and analyzed by FACS. D. The LoxP-PYMT lentiviral 
construct expresses PYMT only after Cre-mediated recombination. Cells were transfected with 
LoxP-PYMT plasmid alone or with the addition of a Cre-expression plasmid and analyzed by 
western blot. E. Model outline of targeting gene expression to specific MEC populations. Cells 
isolated from mice expressing Cre under the control of MEC population-specific promoters were 
infected with lentivirus ex vivo. Transduced cells were then transplanted in syngeneic background 
















































































Figure 3.2. MMTV-Cre MECs express Cre in the luminal and not basal cell lineage. A. In vitro 
MMTV-Cre;mTmG MEC organoid.  GFP expression (green) indicates Cre activity, which overlaps 
with K8-positive luminal cells (red). B. In vitro MMTV-Cre;mTmG MEC organoid. GFP expression 
(green) indicates Cre activity, which does not overlap with K14-positive basal cells (red). C. 
MMTV-Cre;mTmG mouse mammary duct isolates.  GFP expression (green) indicates Cre 
activity, which overlaps with K8-positive luminal cells (red). D. MMTV-Cre;mTmG mouse 
mammary duct isolates. GFP expression (green) indicates Cre activity, which does not overlap 

















































































Figure 3.3. In vitro and in vivo luminal cell linage labeling using MMTV-Cre MECs infected with 
LoxP-Tomato lentivirus. A. Mammary cysts stained with luminal K8 marker (green). B. Mammary 
cysts stained with basal K14 (green) marker. C. Wholemount fluorescent imaging of a Tomato-
positive mammary outgrowth. D. Summary of labeled outgrowths generated from MMTV-Cre 
MECs infected with LoxP-Tomato lentivirus. E. Mammary duct fragments stained with luminal K8 

































































Figure 3.4. In vitro lineage tracing using LoxP-Tomato lentivirus and MECs isolated from mice 
that express Cre under the control of basal and stem cell-specific promoters. MECs were cultured 
in 3D and stained with luminal K8 or basal K14 markers. A.  K14-CreER MECs. B. SMMHC-Cre 




















































Figure 3.5. Generation of tumors from luminal cells using the LoxP-PYMT lentivirus. A. Tumor 
latencies of MMTV-Cre (blue), FVB/NJ (black), MMTV-Cre;mTmG (green), and mTmG (red) 
mouse MECs. B. Sequencing of integrated LoxP-PYMT virus from MMTV-Cre and FVB/NJ MEC 
tumors. C. FACS sorting demonstrating examples of Tomato-positive, GFP-positive, and mixed 
fluorescence tumors.  D. Summary of tumor fluorescence from MMTV-Cre;mTmG and mTmG 
MECs. E-I.  MMTV-Cre;mTmG and mTmG MEC tumor histology examples. Solid 
adenocarcinoma (E), papillary (F), squamous (G), lipid-rich (H), sebaceous-like (I). J. Summary of 



































































































Sequencing of lentiviral DNA intergrated into genomes of generated tumors
Sequence preceeding first LoxP siteFirst LoxP site Multiple coloning site PyMT start
E. F. G. H. I.
MMTV-Cre;mTmG Tumors













































Supplementary Figure 3.1. Mammary epithelial cell populations and transgenic mice expressing 
Cre though cell lineage-specific promoters. Keratin 14 (K14) and leucine-rich-repeat-containing 
G-protein-coupled receptor 5 (LGR5) promoters are active in mammary gland basal and stem 
cells, respectively. The keratin 8 (K8) promoter is active in luminal progenitors and differentiated 
luminal cells (25,35). K14-CreER, LGR5-CreER, and K8-CreER transgenic mice express Cre that 
is regulated by a modified estrogen receptor (ER); and time-selective administration of tamoxifen 
can be used to activate Cre-recombinase activity in mammary stem cells, progenitors, or 
differentiated cells. Basal cells differentiate into myoepithelial cells express that smooth muscle 
22-alpha (SM22α) smooth muscle myosin heavy chain (SMMHC) proteins; thus, SM22α-Cre and 
SMMHC-Cre should express Cre in differentiated basal myoepithelial cells (15,23,24). MMTV is a 
hormone-responsive promoter and induces Cre expression in hormone receptor-positive luminal 






































































Supplementary Figure 3.2. FVB/NJ MEC outgrowths infected with the LoxP-Tomato lentivirus. A. 
Summary of outgrowth fluorescence. B. Outgrowth duct fragment stained with luminal K8 marker. 
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Table 3.1. Summary of latencies and fluorescence of tumors generated from Cre-expressing MECs 
Cell of origin Tamoxifen Number of tumors Average latency (days) 
K14-CreER;mTmG 1 week 10 Tomato-positive 141.4 
 
4 week 5 Tomato-positive 163.4 
  4 week 5 did not grow   
SM22α-Cre;mTmG 
 
1 GFP-positive 113 
  
6 Tomato-positive 123.5 
  
1 mixed 140 
    2 did not grow   
SMMHC-Cre;mTmG 
 
8 GFP-positive 143.25 
  
1 Tomato-positive 162 
    1 did not grow   
LGR5-CreER;mTmG 1 week 3 Tomato-positive 225 
 
1 week 7 did not grow 
 
 
4 week 2 GFP-positive 171 
 
4 week 5 Tomato-positive 182.4 
  4 week 2 did not grow   
K8-CreER;mTmG 1 week 3 GFP-positive 119 
 
1 week 3 Tomato-positive 137.5 
 
1 week 3 mixed 147 
 
1 week 2 did not grow 
 
 
4 week 3 GFP-positive 72 
 
4 week 3 Tomato-positive 122 





DISCUSSION AND FUTURE DIRECTIONS 
 
Breast cancer is a heterogeneous disease, which consists of several subtypes that have 
distinct pathologies and clinical outcomes (1-3).  Several factors may lead to this disease 
diversity. First, various genetic alterations acquired during tumor progression may strongly 
influence tumor phenotype. In addition, intrinsic properties of the tumor cell of origin may also 
define tumor subtype. However, these factors may not be mutually exclusive. 
Breast cancer development and progression have been extensively studied using mouse 
models. Several transgenic mouse mammary tumor models have demonstrated that different 
oncogenes expressed through the same promoter can give rise to distinct tumor types. For 
example, MMTV-PYMT mice give rise to a high proportion of molecularly luminal tumors, 
whereas MMTV-Wnt mice give rise to molecularly Basal tumors (2). These results indicate that 
oncogenes or mutations influence breast cancer subtype. However, most transgenic mouse 
mammary tumor models do not recapitulate the full heterogeneity observed in breast cancer (2,4) 
possibly due to the fact that most transgenic mice do not use promoters that can target oncogene 
expression to the broad spectrum of mouse mammary epithelial cell types. Consequently, 
transgenic mouse mammary tumor models are limited in their ability to test whether specific cell 
populations can contribute to distinct tumor phenotypes.  
As an alternative to transgenic models, Smith et al. demonstrated that diverse mouse 
mammary tumors can be generated using lentiviral infection and mammary epithelial cell 
transplantation techniques (5). However, the question remained if specific mammary epithelial 
cell populations could give rise to unique tumor types. Therefore, to test how the tumor cell of 
origin influences breast cancer phenotype, this dissertation described several novel approaches 
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that utilize lentiviral infection and primary mammary epithelial cell transplantation to transform 
specific mammary epithelial cell populations.  
First, we conducted a study to test how enriched stem, basal, luminal progenitor, and 
differentiated luminal, mammary epithelial cell (MEC) populations contribute to breast cancer 
phenotype. This was achieved by infecting mouse MECs with a previously described lentivirus 
containing the polyoma middle T antigen (PYMT) oncogene (5). Then, specific MEC populations 
were isolated by fluorescence activated cell sorting (FACS) and orthotopically transplanted to 
generate tumors. Our data show that all enriched populations produced tumors with equivalent 
latencies and gave rise to histologically diverse tumors. However, the prevalence of solid 
adenocarcinomas, squamous, papillary, and sebaceous-like histologies varied among the 
transformed populations. Also, molecularly diverse tumors resulted from most of the MEC 
populations, but luminal progenitors exclusively gave rise to tumors that resemble aggressive 
Basal-like breast cancers (2). Finally, compared to the other MEC populations, the differentiated 
luminal population produced tumors that were significantly less metastatic, possibly due to an 
inability of the tumor cells to escape the primary tumor site. These findings show that distinct 
mammary epithelial cells have the capacity to give rise to diverse tumor types; however, the 
tumor cell of origin influences breast cancer subtype and metastatic potential. 
Typically, breast cancers with metaplastic histologies are much more aggressive than 
well-differentiated tumors that maintain some cellular organization similar to normal mammary 
tissue (6). Interestingly, we found that of the enriched populations, more differentiated luminal 
cells gave rise to a higher proportion of well-differentiated papillary and acinar tumors; which are 
characterized by their maintenance of basal and luminal cell organization throughout the tumor 
mass (6). Conversely, basal and stem cell-enriched populations gave rise to more metaplastic 
squamous tumors, consisting of disorganized epithelium intermixed with large keratinized regions 
(6). Of note, mammary stem cell maintenance relies heavily on Wnt signaling (7,8), and 
constitutive activation of β-catenin in mammary epithelial cells promotes squamous tumor growth 
(7,9,10). These findings suggest that stem cell properties may promote squamous tumor 
development. To test this hypothesis, PYMT and stem cell-specific transcription factors can be 
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overexpressed in luminal cells to generate tumors. Then tumor histology can be assessed to 
determine whether the additional expression of stem cell factors enhances squamous tumor 
development.  
Estrogen receptor (ER) status is another factor that influences breast cancer prognosis 
and course of treatment (11). However, it is not known whether specific breast cell populations 
develop into ER-dependent tumors. Our data demonstrate that all MEC populations can give rise 
to ER positive tumors; however, we detected the highest proportion of ER expression in tumors 
derived from differentiated luminal cells. Stem cells, on the other hand, produced the lowest 
percent of ER positive tumors. These findings correlate with the hormone receptor profiles of 
normal MEC populations: differentiated luminal cells express the highest levels of ER, and stem 
cells express the lowest (12). Our tumor data suggest that breast cancer hormone receptor status 
may depend on the intrinsic properties of the tumor cell of origin. Therefore, further experiments 
need to be performed to test whether differentiated luminal cells are the tumor cells of origin for 
hormone-dependent breast cancers. Tumor dependence on estrogen signaling can be examined 
by treating tumor-bearing mice with the ER inhibitor tamoxifen (13), or by transplanting cells into 
ovariectomized mice (14). 
Furthermore, some breast cancer subtypes are much more aggressive and metastatic 
than others (15). Our data demonstrate that tumors generated from differentiated CD133+ luminal 
cells are significantly less metastatic than other population-derived tumors. Therefore, the 
differentiation status of the tumor cell of origin may influence how aggressive and metastatic a 
breast cancer may be. Compounds that can activate mammary epithelial cell differentiation may 
promote the development of more benign tumor lesions from transformed cell populations. 
Because we have identified a population of mammary epithelial cells that gives rise to less 
aggressive tumors, our lentiviral infection model can be used to perform a chemical library screen 
to find drugs that can induce mixed mammary epithelial cells to differentiate into CD133+ luminal 
cells. More specifically, lentivirus-transduced mammary epithelial cells can be examined using 
flow cytometry to quantify the population types present after drug treatment. Then, compounds 
that promote an increased level of luminal CD133+ cell differentiation can be tested in vivo by 
	  	  
107 
treating mice that have received transplants of mixed cells, transduced by the PYMT-expressing 
lentivirus. Following treatment, the tumor metastatic propensity and histology can be examined to 
determine if the identified drugs promote the development of more benign tumor lesions. Since 
we have shown that more differentiated cell populations give rise to less aggressive and well-
differentiated ER+ tumors, this type of treatment may reduce the chance of a patient to relapse 
with an aggressive breast cancer type. Also, the identified compounds may be used in 
combination with standard of care chemotherapies to help maintain tumor cells in a more 
differentiated state, possibly resulting in decreased metastasis and better response to standard of 
care therapy. 
We also found that tumor circulating cell levels were considerably lower in mice bearing 
differentiated luminal cell tumors, indicating that metastasis was decreased in these mice due to 
lack of primary site escape. Primary tumor site escape and metastasis can be promoted by the 
transition of tumor cells from an epithelial state to an invasive mesenchymal state (16). Basal and 
stem-enriched populations have been shown to express the highest levels of genes that regulate 
epithelial to mesenchymal transition (EMT), whereas differentiated luminal cells express high 
levels of genes active in differentiated mammary epithelial cells (17). Therefore, less 
differentiated MEC populations may be primed to undergo EMT and metastasize more readily. 
Differentiated luminal cells, on the other hand, may give rise to tumors that have more epithelial 
properties. As a result, these tumors may be less likely to undergo EMT and escape the primary 
tumor site. Analysis of cell morphology and EMT marker expression in differentiated luminal cell 
tumors may help determine whether these tumors lack EMT properties. This analysis can be 
followed by overexpression of genes that promote EMT, to determine whether metastasis can be 
enhanced in nonmetastatic differentiated luminal cell tumors. 
Although the transformation of enriched MEC populations demonstrated that the tumor 
cell of origin influences several aspects of breast cancer phenotype, tumors were generated from 
enriched and not pure populations. As a result, it is possible that some tumors may have arisen 
from multiple population types. This may explain why we observed extensive inter and intra 
tumoral heterogeneity in our molecular and histological analyses. While limiting dilution 
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transplants may lead to more homogenous tumors, we also developed an additional model of 
targeting gene expression to specific mammary epithelial populations. This was achieved by 
combining lentiviral infection and transplantation methodologies with Cre-LoxP recombination. 
This approach is more cell specific than flow cytometry enrichment techniques. 
Briefly, to target gene expression to specific MEC populations without the need for cell 
enrichment, the lentivirus was designed to express a gene of interest downstream of a LoxP-
flanked translational stop cassette. Then MECs isolated from mice that express Cre under the 
control of population-restricted promoters were infected to activate gene expression in a cell 
specific manner. Using this approach, we performed in vitro and in vivo studies to demonstrate 
that a fluorescent reporter could be targeted to luminal, basal, or stem MEC populations. In 
addition, we were able to generate tumors from distinct populations using the PYMT oncogene. 
However, we also found that tumors could arise in the absence of Cre due to inappropriate 
homologous recombination at lentiviral DNA LoxP sites. As a solution, we demonstrated that 
adding a Cre reporter allele into the Cre lines could identify tumors derived from Cre-expressing 
cells. 
First, we generated tumors from the luminal cell population using MECs isolated from 
mice expressing Cre through the mouse mammary tumor virus long terminal repeat (MMTV) 
promoter (18). Many of these tumors displayed solid adenocarcinoma histology; however, 
papillary and squamous tumors were also detected. Similar to the MMTV-PYMT transgenic 
mouse tumor model (19), the MMTV-Cre mouse MECs appear to preferentially develop into solid 
adenocarcinomas. However, more tumors need to be analyzed to conclude whether this finding is 
significant.  
Next, tumors were generated from stem cells using MECs isolated from mice that 
express Cre through the leucine-rich-repeat-containing G-protein-coupled receptor 5 (LGR5) 
promoter (20). Furthermore, basal cells were targeted for transformation after transducing cells 
isolated from mice that express Cre though keratin (K14), smooth muscle 22-alpha (SM22α), and 
smooth muscle myosin heavy chain (SMMHC) promoters (20-23). Since we used a Cre reporter 
to label tumors derived from Cre-expressing cells, we were able to distinguish between tumors 
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that arose from Cre-mediated recombination and inappropriately pre-recombined virus. 
Unfortunately, few Cre-expressing cells gave rise to tumors from K14-Cre, SMMHC-Cre, and 
LGR5-Cre cell transplants. Therefore, additional tumors need to be generated to fully 
characterize the contribution of basal and stem cell populations to breast cancer phenotype.  
Unexpectedly, inappropriate tumors arose in 90-100% of K14-Cre, SMMHC-Cre, and 
LGR5-Cre cell transplants. However, cells isolated from mice that do not express Cre generated 
tumors only 20% of the time, with significantly longer latencies, suggesting that there is some sort 
of advantage for aberrant tumor growth in transplants where any cells express Cre. We 
hypothesize that Cre-expressing cells may be initially transformed; however, these cells may 
interact with and enhance the transformation or growth of neighboring cell populations that do not 
express Cre. The neighboring cells may be more proliferative and outcompete the initial tumor. A 
recent finding supports the hypothesis that tumors interact with normal cells during cancer 
progression. Melo et al. demonstrated that microRNAs in exosomes secreted from breast cancer 
cells can transform normal neighboring populations (24). Cellular interactions through exosomes 
may also promote inappropriate tumor growth in our tumor transplants. To test this hypothesis, 
exosomes shed from tumor cells could be analyzed for PYMT protein or RNA; and cultured with 
normal cells to determine if they have transformative properties. Also, it would be interesting to 
see if labeled normal MECs can give rise to tumors when transplanted in conjunction with 
differentially labeled tumor cells. Studies like these may provide novel insights into the 
mechanisms of breast cancer development and progression. 
 Besides PYMT, the lentiviral Cre-LoxP system can be used to target other oncogenes to 
the mammary epithelium. For example, expressing Neu, a rat homolog of the human epidermal 
growth factor receptor 2 (HER2) (25), in specific MEC populations may demonstrate that distinct 
cell types preferentially give rise to tumors that resemble HER2-positive breast cancer. So far, we 
have successfully generated mouse mammary tumors using a lentivirus that expresses Neu 
downstream of the LoxP-flanked stop cassette. Unfortunately, these experiments were performed 
before we discovered that aberrant tumors could arise in the absence of Cre. Therefore, 
additional studies need to be performed with the use of a Cre reporter system (26).   
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 Alternatively, our lentiviral methodology can be used to express transposable elements 
instead of oncogenes downstream of the LoxP-flanked cassette. Sleeping beauty transposable 
elements have been extensively used to perform forward genetic screens for cancer gene 
discovery. These transposable elements activate tumor growth through insertional mutagenesis, 
either by promoting endogenous proto-oncogene overexpression or tumor suppressor inhibition 
(27). Because transposable elements do not provide a growth advantage on their own, it is 
unlikely that rare pre-recombined lentiviruses would lead to tumor growth. However, when 
overexpressed in specific MEC populations, transposable elements may provide insights into the 
types of proto-oncogenes or tumor suppressors that drive tumorigenesis in distinct breast cancer 
cells of origin. 
As discussed above, our lentiviral infection and transplantation approaches have several 
advantages to traditional transgenic models. First, we can target gene expression to specific cell 
populations in the mammary epithelium. Second, lentiviral constructs can be easily manipulated 
to express a broad variety of oncogenes. Also, our oncogene expression is restricted to the 
mammary epithelium, in an immune competent mouse. Therefore, we were able to detect 
metastases in distant organs, and can examine how the immune system may influence tumor 
growth and progression.  However, our system has several drawbacks as well. For example, 
lentiviral integration may impact tumor subtype due to insertional mutagenesis, and the number of 
lentiviral integrations into host genome cannot be regulated. Also, transplantation of enriched 
populations gave rise to diverse tumor types, and it is not clear whether that was due to the cell of 
origin or lack of population purity. Finally, tumors generated with the Cre-LoxP lentiviral system 
arose in the absence of Cre activity, demonstrating that our oncogene expression is not tightly 
regulated in the lentivirus.  
Several alternative approaches can be used to avoid the disadvantages of the lentiviral 
infection and transplantation models to generate tumors from specific mammary epithelial cell 
populations. In one such approach, an internal ribosome entry site and PYMT oncogene could be 
knocked into the mTmG Cre reporter mouse line downstream of green fluorescent protein (GFP) 
(26). This way, the oncogene would be integrated in one locus of the mouse genome, and would 
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not impact any essential genes by insertional mutagenesis. Also, the PYMT oncogene would only 
be expressed in the presence of Cre recombinase. To activate PYMT expression in specific 
mammary epithelial cell populations, adenoviruses expressing Cre under the control of cell 
lineage-specific promoters could be used to infect the mammary epithelium through intraductal 
injection (28). Since adenoviruses do not integrate into the host genome (29), insertinal 
mutagenesis due to viral integration would not be an issue. Also, intraductal injection of the virus 
would limit oncogene expression to the mouse mammary epithelium, and would also eliminate 
the need for backbreeding mice because syngeneic transplantation would not be necessary. 
Finally, since tumors would be fluorescently labeled, metastases and cellular interactions with 
non-tumor cells could be easily identified. 
 In summary, we have developed two mouse breast cancer models that can be used to 
target oncogene expression to specific MEC populations. First, we utilized lentiviral and MEC 
transplantation methodologies, combined with flow cytometry population enrichment, to generate 
tumors from basal, stem, and luminal cell populations. Our results show that diverse tumors can 
arise from specific MEC populations; however, the tumor cell of origin also influences breast 
cancer subtype and metastatic potential. Second, we demonstrated that lentiviral infection and 
transplantation techniques can be combined with Cre-LoxP recombination to transform specific 
MECs. However, we also determined that a Cre reporter system is essential in order to identify 
tumors arising from Cre-expressing cell populations.  
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